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ABSTRACT OF THESIS
Involvement of the Sigma-1 Receptor in Methamphetamine Mediated Changes to
Astrocyte Structure and Function
Methamphetamine is a highly addictive psychostimulant drug. There are currently
no FDA-approved pharmacological treatments for methamphetamine addiction.
Pharmacologically, (+)-methamphetamine is a dopamine releasing agent and dopamine
transporter substrate that redistributes dopamine from intracellular vesicles via the
vesicular monoamine transporter 2 (VMAT2) and reverses the direction of dopamine
transport in the dopamine transporter. Methamphetamine, cocaine, and other drugs of
abuse are also sigma-1 receptor ligands, and previous studies have demonstrated the role
of the sigma-1 receptor in modulating the behavioral and cellular effects of these drugs.
However, almost all these studies were conducted in cell culture systems or with emphasis
on the neuronal effects of sigma-1 receptor binding.
In the literature, the sigma-1 receptor localizes robustly within neurons throughout
the brain. However, there are conflicting results regarding localization in astrocytes. Here,
immunohistochemical experiments were conducted on rat brain tissue containing either the
nucleus accumbens or the prelimbic cortex, two brain regions critical in mediating drugseeking behavior, in order to confirm expression of the sigma-1 receptor in astrocytes. It
was determined that the sigma-1 receptor is ubiquitously expressed among neurons and
modestly expressed among glial fibrillary acidic protein (GFAP)-positive astrocytes. There
were no noted statistically significant differences between the proportion of cell types
expressing the sigma-1 receptor in the prelimbic cortex and the nucleus accumbens. Next,
the effect of methamphetamine and the role of the sigma-1 receptor on astrocytic
morphology and sigma-1 receptor distribution were probed by incubating slices of striatal
tissue in methamphetamine solution with or without the sigma-1 receptor antagonist BD1063 and the sigma-1 receptor agonist PRE-084. Only the methamphetamine-treated slice
exhibited a significantly different amount of stellations than the other slices. The sigma-1
receptor antagonist BD-1063 and PRE-084 abolished the redistribution of sigma-1 receptor
to the processes of the astrocytes induced by methamphetamine. Thus, the data confirms
that astrocytes in both the prelimbic cortex and nucleus accumbens express the sigma-1
receptor. Moreover, methamphetamine induces statistically significant redistribution of the
sigma-1 receptor that is abolished by BD-1063 and PRE-084.
KEYWORDS: methamphetamine, astrocytes, sigma-1 receptor
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CHAPTER 1. MECHANISMS OF METHAMPHETAMINE ACTION
1.1 Methamphetamine as Drug of Abuse
The consequences of methamphetamine abuse place significant burden on the
economy of the United States. According to a 2009 report, methamphetamine abuse
cost an estimated $23.4 billion to citizens of the United States (Nicosia et al., 2009).
Results from the United State National Survey on Drug Use in 2016 suggest that a
significant proportion (1.6 million) of the population had used methamphetamine in the
past year (SAMHSA, 2017). Moreover, methamphetamine addiction is difficult to treat
due to high rates of relapse. It was estimated in a sample of patients admitted
specifically for methamphetamine abuse that 61% relapsed within a year after
discharge and an additional 25% during years 2-5 following discharge (Brecht and
Herbeck, 2014). Additionally, methamphetamine use is increasing in the United States
according to recent estimates (Jones et al., 2020). There are currently no FDA-approved
pharmacological therapies for the treatment of psychostimulant abuse, highlighting the
urgent need for research into the mechanisms by which psychostimulant dependence
and addiction develop. Three drugs in the class of substances known as
psychostimulants are cocaine, amphetamine (AMP), and methamphetamine (METH).
All three drugs elevate dopamine concentrations in the ventral striatum, contributing to
their reinforcing effects, yet they do so by distinct mechanisms, with AMP and METH
sharing similar mechanisms of extracellular dopamine elevation. The following is a
discussion of these mechanisms.

1.2 Mechanism of AMP/METH-Mediated DA Release

1.2.1 Actions at DAT
Among the psychostimulants, there are two general mechanisms of action.
Drugs can either promote the release of dopamine into the synaptic cleft or they can
1

block the reuptake of dopamine into the presynaptic neuron. Both of these
mechanisms require the dopamine transporter. The crystal structure for a
humanized Drosophila melanogaster dopamine transporter in complex with several
ligands has been solved. Both methamphetamine and amphetamine bind in a site
very close to that of dopamine. The basic amine group on both molecules interacts
with an aspartate residue (D46), as does the basic amine group on dopamine. Both
d-amphetamine and d-methamphetamine form a hydrogen bond with the carbonyl
group on the phenylalanine residue F319. That amphetamine, methamphetamine,
and dopamine share very similar poses in the binding site (allowing for interaction
with the transporter subsite) suggests that it is plausible that amphetamine and
methamphetamine act as substrates for the dopamine transporter rather than simple
inhibitors (Wang et al., 2015). Cocaine, on the other hand, does not allow for this
interaction and can therefore be considered a pure inhibitor of the dopamine
transporter (DAT). Indeed, cocaine is a classical dopamine reuptake inhibitor that
stabilizes the outward-facing conformation of the dopamine transporter by binding
to a site near that of dopamine in models of the dopamine transporter based on the
structure of the bacterial leucine transporter (LeuT; Beuming et al., 2008).

Experiments examining the uptake of radiolabeled amphetamine into rat
brain synaptosomes demonstrate that a variety of reuptake inhibitors, including
methamphetamine, can inhibit the transport of amphetamine into synaptosomes,
suggesting that amphetamine acts as a substrate, rather than an inhibitor of
dopamine uptake (Zaczek et al., 1991) at the concentrations assayed (5 nM). The
dopamine transporter is electrogenic, and transport is coupled with influx of 2 Na+
ions and 1 Cl- ion. This amphetamine uptake was oubain-sensitive (oubain inhibits
the Na+/K+ ATPase), an effect that can be linked to the requirement of inward
sodium flux by the Na+/K+-ATPase is required to maintain the concentration
gradient of Na+ and K+. Experiments in Xenopus oocytes transfected with DAT
revealed that cocaine can block the inward current generated by DAT.
Amphetamine, on the other hand, generates an inward current, suggesting that it

2

drives cation transport into the cell, and the I-V plots for classical uptake inhibitors
and releasing agents are distinct (Sonders et al., 1997).

Further evidence that cocaine and amphetamine/methamphetamine differ in
their action at the dopamine transporter resulted from early work that demonstrated
that cocaine can block the increase in blood pressure induced by tyramine, an amine
that also releases catecholamines like amphetamine and methamphetamine, yet
both drugs alone elevate blood pressure (Tainter and Chang, 1927). This finding
was corroborated by studies in which other pure dopamine reuptake inhibitors such
as benzotropine and methylphenidate could inhibit the efflux of labeled dopamine
induced by amphetamine in the rat corpus striatum and in HEK293 cells expressing
the dopamine transporter, respectively (Liang and Rutledge, 1982; Simmler et al.,
2013). This suggests that DAT is necessary for the dopamine-releasing properties
of amphetamine.

Evidence for the fact that there is more to amphetamine-mediated dopamine release
than simple reuptake inhibition comes from a study that suggests that the affinity
at the dopamine transporter cannot explain the behavioral potency of amphetamine
(Ritz et al., 1987). In this case, behavioral potency was measured in primates.
Essentially, monkeys were trained to self-administer a standard dose cocaine.
Subsequently the solution was switched to contain varying concentrations of the
test drug. The rate of responding to the test drug was utilized as the metric to
calculate behavioral potency. The behavioral potency of (+)-amphetamine cited in
this study was 0.20, similar to the drug mazindol, yet the binding affinity of
mazindol is some 156 times greater than the affinity of (+)-amphetamine for DAT.

Inward transport of AMP as a substrate at DAT is critical for its dopaminereleasing actions. However, as amphetamine and methamphetamine are both
lipophilic weak bases (meaning they can pass through the plasma membrane), it is
plausible that these compounds do not require transport via DAT at higher
concentrations, but rather can cross the plasma membrane by passive diffusion
3

(Mack and Bönisch, 1979). Moreover, the dopamine transporter does not merely
act to transport amphetamine or methamphetamine into the cell; indeed, the
dopamine transporter is critical for the release of dopamine observed during
amphetamine treatment (Kahlig et al., 2005; Pifl et al., 1995). However, actions at
the dopamine transporter cannot explain the entire picture of how AMP mediates
release of dopamine. For example, if DAT alone mediates the effects AMP and its
affinity for DAT is so low, then why is AMP so potent at eliciting stimulant effects?
Why does a smaller dose of methamphetamine elevate extracellular dopamine in
the nucleus accumbens to similar levels or even greater levels as a larger dose of
cocaine (Zhang et al., 2001; Nakagawa et al., 2011), despite its markedly decreased
affinity at DAT (Ritz et al., 1987)?

1.2.2

Vesicular Actions of AMP/METH

In dopaminergic neurons, synaptic vesicles are loaded with dopamine
primarily by the protein VMAT2. The other vesicular monoamine transporter,
VMAT1, is localized primarily in adrenal chromaffin cells and other peripheral cell
types (Schuldiner et al., 1995). The operation of VMAT is driven by a proton
gradient (high concentration of protons in the vesicle, lower concentration in the
cytosol) that is generated by a vacuolar H+-ATPase. Indeed, amphetamine collapses
the pH gradient maintained by the vacuolar H+-ATPase, particularly at high
concentrations. However, at low concentrations the loss of the pH gradient cannot
account for dopamine released from rat brain synaptic vesicles (Floor and Meng,
1996). VMAT then transports monoamines into the vesicle by transporting protons
out of the vesicle; two protons are exchanged for a positively charged monoamine
substrate. Given that this process is proton driven, it is plausible that certain weak
bases might diffuse through the vesicle membrane and disrupt the proton gradient.
Indeed, this is the case seen when adrenal chromaffin cells are treated with the weak
base chloroquine, and a similar effect is observed when the vacuolar H+-ATPase is
inhibited with bafilomycin (Pothos et al., 2002). Both AMP and METH are also
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weak bases and both induce redistribution of dopamine from vesicles. Thus, the
weak base hypothesis of amphetamine/methamphetamine action was proposed.

The situation is not as simple as passive diffusion of amphetamine into
synaptic vesicles and subsequent alkalinization of those vesicles; there appears to
be stereoselectivity in terms of which isomer of methamphetamine inhibits VMAT2
more, with the (+)-isomer having greater potency (Peter et al., 1994). These
findings are recapitulated in an experiment in VMAT-expressing HEK cells treated
with a fluorescent substrate for VMAT; both S-(+)-amphetamine and S-(+)methamphetamine inhibited uptake of this fluorescent substrate more than R-(-)
isomers. Simple inhibition of VMAT2 cannot explain the dopamine releasing
effects of AMP or METH since reserpine, an inhibitor of VMAT2, actually depletes
the presynaptic terminal of dopamine, presumably by allowing dopamine to
accumulate in the cytosol where it is vulnerable to metabolism by monoamine
oxidase enzymes. Rather, there is evidence that amphetamine acts as a substrate for
VMAT that is transported into the vesicle by proton antiport and alkalinizes the
interior of synaptic vesicles. The fluorescent substrate, FFN206, was used to label
vesicles in the Drosophila melanogaster brain revealing labeling of nerve terminals
throughout the D. melanogaster brain. The animals were transfected with dVMATpHluorin, a fluorescent, pH-sensitive molecule inserted into the dVMAT protein.
This allowed for simultaneous pH data and VMAT transport activity data to be
recorded. Amphetamine dose-dependently increased the pH within vesicles,
confirming the hypothesis that it acts as a weak base. This alkalinization was
blocked for both amphetamine and methamphetamine when dDAT (Drosophila
dopamine transporter) was knocked out, highlighting the fact that both AMP and
METH are substrates for DAT. To determine whether the alkalinization of the
vesicle was primarily a function of the weak base properties of AMP and METH, a
substrate that could not be protonated (MPP+) was assayed. It was found that MPP+
could also alkalinize vesicles albeit with lower potency than AMP or METH. This
suggests that the H+ antiport mediated by substrate uptake is sufficient to alkalinize
the vesicle (Freyberg et al., 2016). Thus, pure weak bases like chloroquine, which
5

lacks any affinity for VMAT2, displace monoamines from vesicles by a
fundamentally different mechanism than amphetamine or methamphetamine; the
unmodified weak-base hypothesis is not sufficient to account for the dopamine
released by AMP or METH. Rather, AMP and METH are substrates for VMAT,
and the substrate-coupled proton antiport action of these compounds is critical for
alkalinization of the vesicle and subsequent displacement of dopamine (Hiranita
and Freyberg, 2016). The only difference between this hypothesis and the general
weak base hypothesis is that METH and AMP are also VMAT2 substrates whereas
chloroquine is purely a weak base. This modified hypothesis does not preclude the
possibility that AMP and METH can traverse the membrane of vesicles, but rather,
it states that the primary mechanism by which AMP and METH enter the vesicle is
by inward transport via VMAT2.

1.2.3

Hypotheses of AMP/METH-Mediated DA Release

The net effect of AMP/METH administration, that is, the release of DA
from the presynaptic nerve terminal, cannot be explained by the actions of these
compounds at VMAT, nor can simple inward transport mediated by DAT explain
the observation that AMP and METH promote dopamine release. Moreover,
dopamine is a substrate for the monoamine oxidase enzymes which are localized in
the cytosol and in mitochondria – this means that any dopamine displaced from
vesicles must rapidly exit the presynaptic terminal of the dopaminergic neuron, or
it is vulnerable to degradation by monoamine oxidase enzymes (see 1.2.4 for
AMP/METH interaction with MAO enzymes).

This is the basis of the facilitated exchange diffusion model of amphetamine
action (Figure 1.1) which proposes that dopamine transporters bind intracellular
dopamine due to the overwhelmingly high cytosolic concentration of dopamine in
the presence of METH/AMP (due to displacement of dopamine from vesicles to
the cytosol) and then release it to the extracellular milieu. The inward-facing
conformation of the DAT would be transient due to low intracellular sodium
6

concentrations, but AMP, which both promotes the inward-facing conformation
and increases intracellular dopamine would facilitate greater release of dopamine
via DAT. This model is known as the facilitated exchange diffusion model and was
initially used to describe reverse transport by the glucose transporter (Stein, 1967).
As described above, a key facet of this model is that extracellular sodium
concentrations are high. The presence of the sodium ion stabilizes the conformation
of the dopamine transporter such that it is normally locked in its outward,
extracellular-facing conformation (i.e. in the absence of substrate). When
amphetamine binds to DAT, it induces a conformational change and is released into
the cytosol, alongside the sodium and chloride ions. Since intracellular sodium
concentrations are much lower than the extracellular concentration, the inward open
conformation of DAT is transient, but if intracellular dopamine concentrations were
high enough, the dopamine could bind to the inward open conformation and be
transported out of the cell. The involvement of sodium in stabilizing the
conformation of monoamine transporters was initially proposed by Bogdanski and
Brodie in 1969 (Bogdanski and Brodie, 1969). In those experiments, it was found
in rat heart tissue slices that media not containing sodium (i.e. intracellular sodium
concentration is higher than extracellular sodium concentration) favored release of
norepinephrine while sodium-rich media favored uptake of norepinephrine (more
[3H]norepinephrine remained in the tissue in sodium-rich conditions than in
sodium-poor conditions). Additionally, it was also found that potassium plays a role
in the net inward flux of norepinephrine, as K+ has an antagonistic effect on
norepinephrine transport into the cell. The authors hypothesized that K+ competes
for the same binding site as Na+. When the transporter faces inwards, the Na+
binding site is exposed to the cytosol where K+ concentrations are high. In the
presence of high K+, the transporter releases both the norepinephrine and the Na+
ion.

The work of Fischer and Cho provided critical evidence for the facilitated
exchange diffusion model of amphetamine action (Fischer and Cho, 1979). First, it
was demonstrated that the release of [3H]dopamine by d-AMP was temperature7

dependent, suggesting that active transport is required for dopamine release.
Second, it was demonstrated that dopamine release is partially saturable, suggesting
that a population of a particular protein mediating (DAT) dopamine release by dAMP. Third, the observed release was blocked by cocaine, recapitulating work
suggesting that AMP requires the dopamine transporter for its function. Fourth,
decreasing extracellular sodium concentrations shifted the dose-response curve of
dopamine released vs. concentration of AMP to the right, meaning sodium plays a
role in dopamine release by DAT. The latter finding supports the hypothesis that
the sodium ion plays a role in the uptake of substrate by stabilizing the open
conformation of DAT. It is important to note that increasing the concentration of
intracellular sodium also facilitates efflux both in the absence and presence of AMP
(Khoshbouei et al., 2003). That simply increasing intracellular sodium can increase
efflux contradicts the facilitated exchange diffusion hypothesis because this
suggests that there is no requirement for inward transport in order to promote efflux.
Experiments utilizing the Drosophila melanogaster dopamine transporter (dDAT)
co-crystallized with Na+ suggest that Na+ alone promotes a transition from the apo
(completely unbound state) state to the outward open state in which the substrate
binding site is exposed. Binding of Na+ also stabilized the inner gate of dDAT and
destabilized regions involved in promoting the outward open configuration of
DAT. When dopamine is bound to the Na+-bound dDAT, dDAT favors an outward
closed conformation. This suggests that dopamine and sodium binding are
prerequisites for transition to the closed conformation (Nielsen et al., 2019). The
results from Khoshbouei and coworkers suggest that these properties are retained
in the inward-facing conformation. Importantly, because the concentration of Na+
is lower intracellularly than extracellularly, the stabilized, inward open
conformation is transient. However, due to elevated intracellular dopamine, the
likelihood of dopamine binding to the inward-facing open conformation is
increased despite the lower Na+ concentration in the cytosol.
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Figure 1.1 The facilitated exchange diffusion model. The red circles represent the sodium
ion, the green triangles, amphetamine, and the purple triangles, dopamine. Binding of
sodium to the unbound state of DAT (Apo-DAT) induces a conformational change that
allows dopamine or amphetamine to bind to its binding site on the dopamine transporter.
A series of conformational changes occur in the structure of DAT which results in inward
transport of dopamine. The inward-facing conformation of DAT binds intracellular
sodium and dopamine. In this model the elevated intracellular concentration of dopamine
mediated by AMP actions permits dopamine binding to the inward-facing, sodium-bound
conformation of DAT. Once dopamine binds, DAT undergoes a conformational change,
releasing dopamine to the extracellular space.
Dopamine efflux mediated by injection of dopamine into the giant
dopaminergic neuron of Planorbis corneus (pond snail) can be blocked by
dopamine transporter inhibitors such as nomifensine, suggesting that the dopamine
transporter mediates both efflux of dopamine from the neuron and also influx of
dopamine into the neuron. This suggests that increased intracellular concentration
of dopamine, perhaps that induced by dopamine redistribution from vesicles due to
the action of AMP on VMAT, is sufficient to promote release of dopamine through
the dopamine transporter. In other words, despite lower intracellular Na+
concentration, an elevated concentration of intracellular dopamine is sufficient to
promote binding to the inward-facing conformations of DAT. In the same study,
amphetamine was injected directly into the giant dopaminergic neuron, and this
9

dramatically increased the concentration of cytosolic dopamine. Moreover, as
expected, amphetamine decreased the quantal size in PC12 cells, measured by
evoking release with KCl (Sulzer et al., 1995). The facilitated exchange diffusion
model assumes that AMP binds to DAT and induces an inward-facing conformation
due to inward transport. Because dopamine release occurred even when
amphetamine was directly injected into the cell, the facilitated exchange diffusion
model cannot explain dopamine release in these experiments.

Other hypotheses have emerged to explain dopamine efflux mediated by
AMP. The advent of rapid patch clamp technology has enabled researchers to
observe very rapid, large events that are not stoichiometrically associated with
substrate translocation (i.e. the magnitude of the charge movement exceeds that
associated with substrate transport). This uncoupled ion conductance has been
observed for monoamine transporters such as SERT (Mager et al., 1994) and DAT
(Sonders et al., 1997). The existence of these uncoupled currents suggests a
channel-like mode of conductance in DAT. It has been suggested, based on outsideout patch clamp experiments in HEK293 cells stably expressing hDAT, that this
channel-like conductance is also associated with the efflux of dopamine induced by
amphetamine (Kahlig et al., 2005). In other words, amphetamine promotes this
channel-like mode of conductance and this state of the dopamine transporter
promotes bursts of dopamine release via DAT in the presence of AMP. It is
important to note that much slower events were also observed; the authors termed
these slower events as “transporter-like behavior.” This transporter-like behavior
was suggested to be associated with reversal of the direction of transport by DAT.
In contrast, the “channel-like” behavior was characterized by rapid burst-firing
events. Both of these observed behaviors were shown to be responsible for
dopamine efflux. The channel-like events could be blocked completely by cocaine
and cannot be evoked by extracellular dopamine. It was also found that intracellular
Na+ is a requirement for these channel-like events and that in the presence of
intracellular Na+ and AMP, the open probability of the DAT channel was increased.
Further evidence for the connection between these rapid burst-like events and the
10

channel-like properties of DAT was found in comparing the channel flux ratio (ions
transported per molecule of dopamine in the channel-like mode) with the
transporter flux ratio (ions transported per molecule of dopamine in the transporterlike mode); the channel flux ratio is substantially higher than the transporter flux
ratio. This is to be expected, since the channel-like mode of transported does not
necessarily require ion binding to the transporter, so the number of ions that can
pass through is increased. Apart from this channel-like mode of dopamine transport,
there is another hypothesis for how AMP mediates the release of dopamine from
neurons via DAT: by direct modification of DAT itself.

The dopamine transporter contains several serine/threonine residues that
can be phosphorylated, and this phosphorylation could potentially regulate efflux
of dopamine mediated by AMP. Experiments in PC12 cells suggest that
phosphorylation by PKC drives downregulation of DAT at the plasma membrane
and that phosphorylation by PKC leads to reversible internalization of DAT –
phosphorylation by PKC leads to trafficking to recycling endosomes (Melikian and
Buckley, 1999). It has also been demonstrated that inhibition of PKCβ as well as
the canonical PKC isoforms (α, β1, β2, and γ) can inhibit efflux of dopamine
mediated by amphetamine in HEK293 cells transfected with DAT. Moreover, it
was found that PKCβ1 and PKCβ2 are associated with DAT and overexpression of
PKCβ2 enhances AMP-mediated dopamine efflux (Johnson et al., 2005). However,
PKCβ requires activation by some intracellular or extracellular signal. How can
METH or AMP stimulate PKCβ to facilitate dopamine efflux? One possibility is
that another receptor, one which binds METH and AMP, activates PKC, thus
mediating dopamine efflux.

METH and AMPH are agonists of a receptor in the family of receptors
known as trace amine-associated receptors (TAARs). The receptor known as
TAAR1 is most relevant to the action of METH and AMP (Liu and Li, 2018). The
endogenous ligands for this receptor are trace amines such as octopamine and ptyramine. As phenethylamines, these compounds are structurally similar to AMP
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and METH. In HEK293-DAT cells transfected with rhesus monkey TAAR1, both
METH and dopamine stimulated cAMP production mediated by TAAR1 (Xie and
Miller, 2007). It was observed that there was an abrupt halt in [3H]dopamine uptake
in the presence of TAAR1, DAT, and dopamine. This abrupt halt could be
prevented by PKA and PKC inhibitors. A mutation of residue (T62D) of the DAT
induced efflux of dopamine, suggesting that phosphorylation of this threonine
residue can promote a conformation of the DAT amenable to efflux of dopamine
(Fraser et al., 2014). Additionally, it was observed that both dopamine and
methamphetamine can increase efflux of [3H]dopamine in the presence of TAAR1
and DAT but not in the presence of DAT alone. This efflux could be blocked by
methylphenidate or a PKC inhibitor, in the case of METH. High intracellular
concentrations of dopamine mediate efflux through a PKC-independent
mechanism. That METH could not evoke dopamine efflux in the absence of
TAAR1, suggests that TAAR1 plays a critical role in METH-mediated dopamine
efflux.

These results were recapitulated in studies utilizing WT and TAAR1-/mouse synaptosomal preparation as well as rhesus monkey synaptosomal
preparation: METH decreased uptake significantly in the WT and rhesus
preparations while it did so much less in the TAAR -/- preparation. This uptake
inhibition could be blocked by inhibitors of PKC and PKA. Dopamine release was
first measured in HEK293-DAT cells. The results suggested that only when
HEK293-DAT (i.e. not expressing TAAR1) cells are loaded with high
concentrations of dopamine can release be evoked by METH. The PKC and PKA
inhibitors blocked TAAR1-mediated effects of METH on dopamine efflux in the
wildtype synaptosomal preparations and DAT-TAAR1 HEK293 cells that had been
preloaded with high concentrations of dopamine. Inhibition of PKC and PKA only
reduced the effect of METH on dopamine efflux in preparations from wildtype
mice, with no effect observed in TAAR1-/- preparation (Xie and Miller, 2009).
Thus, both experiments in culture and experiments using tissue support the
hypothesis that TAAR1 induces dopamine efflux via PKC but not PKA.
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Interestingly, TAAR1 activation by AMP could plausibly mediate the
endocytosis of DAT via RhoA, the latter being activated by the Gα13 G-protein.
TAAR1 coupled to Gα13 is localized specifically in the endoplasmic reticulum. In
contrast, activation of PKA mediated by AMP via TAAR1 occurs in a broader set
of compartments (Underhill et al., 2019). Indeed, robust DAT internalization
mediated by methamphetamine has been observed in HEK293-DAT-TAAR1 cell
culture (Xie and Miller, 2009).

Thus, there are several proposed mechanisms for AMP/METH-mediated
dopamine release from presynaptic terminals subsequent to redistribution of
dopamine to the cytosol. The oldest model for AMP-mediated release is the
facilitated exchange diffusion model and hence there is a substantial body of
experimental evidence supporting this hypothesis of AMP-mediated dopamine
release. However, newer hypotheses have emerged, and these hypotheses are
equally convincing as the facilitated exchange diffusion model.

1.2.4

Effects on DA Synthesis and Metabolism

Not only do AMP and METH release dopamine from the presynaptic
terminals of dopaminergic neurons, they can also alter the synthesis and
metabolism of dopamine. The most direct mechanism by which they do so is by
inhibition of monoamine oxidase enzymes. Indeed, METH inhibits the A- isoform
of monoamine oxidase (MAO-A) as well as the B-isoform of monoamine oxidase
(MAO-B). This was demonstrated in crab-eating monkey brain mitochondrial
monoamine oxidase (primarily MAO-B) and synaptosomal monoamine oxidase
(primarily MAO-A) by utilizing β-phenethylamine as the MAO-B substrate and
serotonin or dopamine (dopamine is also metabolized by MAO-B) as MAO-A
substrates. In these experiments, METH was more effective at inhibiting MAO-A
than MAO-B, and it was also shown that AMP inhibits these monoamine oxidase
enzymes as well (Egashira et al., 1987). It has been shown that the D-(+)
enantiomers of both METH (Suzuki et al., 1980) and AMP (Mantle et al., 1976) are
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superior inhibitors of MAO, particularly MAO-A. The (+) isomer of amphetamine
has a Ki of 33.8±4 µM at MAO-A and a Ki of 161±32 µM at MAO-B. The (+)
enantiomer of methamphetamine is an inferior inhibitor of monoamine oxidase
enzymes, with a Ki of 110±4 µM at MAO-A and 272±83 at MAO-B (Robinson,
1985). This inhibition of monoamine oxidases prevents the degradation of
dopamine released from vesicles by METH or AMP, allowing more dopamine to
be released from the neuron.

Another potential effect of AMP is that it can increase activity of tyrosine
hydroxylase (TH), the rate-limiting enzyme in the biosynthesis of dopamine
(Kuczenski, 1975). In neurons, it has been demonstrated that there are two pools of
synaptic vesicles, the readily releasable pool (vesicles that are docked to the
presynaptic membrane) and the reserve pool (a third pool, the recycling pool is less
relevant to upregulating TH activity). Altering the duration of a train of action
potentials allows one to distinguish between these two pools – the shorter train
reveals information regarding the readily releasable pool while the longer train
reveals information regarding the reserve pool. By varying these train lengths,
different pools of vesicular dopamine could be interrogated using fast-scanning
cyclic voltammetry. It was demonstrated in the dorsal striatum that 10 mg/kg
amphetamine increases dopamine concentrations upon short trains (probing the
readily releasable pool) and decreases dopamine concentration upon long stimulus
trains (probing the reserve pool). In the ventral striatum, both 1 mg/kg and 10 mg/kg
increased dopamine concentration for the short train and the intermediate train,
indicating an increase in dopamine released from the readily releasable pool and
the recycling pool. Strangely, there was no decrease in dopamine concentration in
the reserve pool in the ventral striatum upon trains of action potentials. There was,
however, a trend towards depletion of dopamine in the reserve pools when tonic
release of dopamine was examined, supporting the hypothesis that amphetamine
increases the size of pools that are primed for release while it decreases the size of
reserve pools (Covey et al., 2013). Indeed, it has been demonstrated that when
radiolabeled tyrosine is incubated with rat striatal slices, the dopamine that is
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released is also radiolabeled, since tyrosine is metabolized by TH to L-DOPA and
then by aromatic amino acid decarboxylase to dopamine.

This amphetamine-induced enhancement of dopamine synthesis has been
demonstrated to be calcium dependent, as EGTA (a calcium chelator) injected
directly into the mouse striatum inhibits the enhancement of radiolabeled dopamine
synthesis by amphetamine (Fung and Uretsky, 1982). Several intracellular kinases
are dependent on calcium for full activation. Therefore, it is plausible that a protein
kinase stimulated by calcium (since EGTA inhibits enhancement of dopamine
synthesis) is responsible for phosphorylating TH and enhancing its activity. Indeed,
it has been observed that TH can be modulated by phosphorylation (Dunkley et al.,
2004). It has also been demonstrated that TAAR1 can activate TH when TAAR1 is
stimulated by 3-iodothyronamine (Zhang et al., 2018), meaning that TAAR1 can
directly stimulate TH when stimulated. Whether TAAR1 stimulation by METH or
AMP can directly activate TH is still unknown.

Thus, AMP and METH not only redistribute dopamine from vesicles to the
cytosol and promote the release of dopamine, they also have effects on dopamine
synthesis and metabolism. Inhibition of monoamine oxidase generates conditions
favorable towards accumulation of free intracellular dopamine while stimulation of
dopamine synthesis could mediate some of the longer-term effects of AMP and
METH.

1.3 Astrocytes
1.3.1 General Role of Astrocytes in the CNS
1.3.1.1 History of Astrocytes

For many years, it was thought that neurons are the true workhorses of the
central nervous system and that glia were literally the “glue” that held it together (the
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word glia is derived from the Greek word for glue). In fact, when the concept of glia
was first introduced by Virchow in 1856, glia were simply considered the substrate in
which neural tissue was located. Initially, the cells that constituted glia were called a
number of different names. Camillo Golgi, using his characteristic silver staining
method, demonstrated that glia are a population of cells distinct from neurons. The term
astrocyte was not introduced until 1895 when Michael von Lenhossék used the term to
describe a subset of parenchymal glia. In fact, the cells with star-like projections and
end feet encircling small blood vessels observed by Golgi were astrocytes. Late in the
19th century and early in the 20th century, it was realized that astrocytes are much more
than the simple “glue” that holds neurons together. Ernesto Lugaro proposed a
metabolic role for astrocytes, with their fine processes that invade synapses. Carl
Ludwig Schleich proposed that astrocytes actively control the flow of information.
Ramon y Cajal suggested that astrocytes regulate the vasculature in the brain by
constricting or dilating capillaries. One of Ramon y Cajal’s students, Fernando De
Castro hypothesized that astrocytes release neuroactive substances that can modulate
synaptic transmission – a precursor of the gliotransmitter hypothesis (Verkhratsky and
Nedergaard, 2018).

1.3.1.2 Astrocyte Development

Astrocytes develop from other astrocytes (via mitosis; certain states, described later
can promote proliferation of astrocytes), from progenitor cells called radial glial cells, and
from NG2 glial cells (Verkhratsky and Nedergaard, 2018). During development, neurons
and astrocytes are derived from the same neural stem cells. Once these cells have specified
their fate by expressing several genes, they migrate along radial glial cells (which
themselves can become astrocytes). Even after radial glial cells retract their processes
(hence no longer function as scaffolds to direct cell migration), astrocytes still appear to
migrate during development. When the astrocytes reach their final destination, they begin
expressing GFAP. Although GFAP can sometimes be an unreliable marker of astrocyte
maturation and expression levels can vary significantly, GFAP is the gold standard in the
field; its expression is considered a hallmark of astrocyte identity. However, GFAP
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expression varies regionally (Chai et al., 2017) and in certain pathological conditions (such
as Alzheimer’s disease), it can be expressed by neurons (Hol et al., 2003). Other markers
such as S100β, Aldh1L1, and Glt1 have also been used to identify astrocytes in the past.

1.3.1.3 Potassium Buffering Roles of Astrocytes

One important role of astrocytes is to maintain ion homeostasis in CNS tissue. Neurons
rely on the concentration gradients of Na+ (generally high extracellularly and low
intracellularly), K+ (generally low extracellularly and high intracellularly), and Cl(generally high extracellularly and low intracellularly) to generate graded and action
potentials. When a neuron is depolarized in physiological conditions, sodium enters the
cell and potassium exits the cell. If the depolarization reaches a certain threshold, the cell
will fire an action potential. During sustained spike trains (several action potentials in a
short period of time), a significant amount of potassium leaks out of the neuron, increasing
the extracellular concentration of potassium. If extracellular potassium concentrations are
too high, the neuron will fire action potentials repeatedly, which can result in seizure-like
behavior. Astrocytes act as buffers of potassium. Astrocytes are also more permeable to
potassium than neurons, due in part to high expression of inwardly rectifying potassium
channels (Kir) that are open at resting membrane potential. Active transport (via Na/K
ATPase, the same one expressed by neurons) and cotransport (via Na+-K+-Clcotransporter) mediate entry of potassium into the astrocyte (Kofuji and Newman, 2004).
In this mode of potassium buffering, individual astrocytes take up excess K+ and store it,
releasing it back to the extracellular space when extracellular potassium concentrations
have decreased. Naturally, water is drawn into astrocytes by potassium influx, resulting in
cell swelling. The other type of extracellular potassium concentration regulation
demonstrated by astrocytes is spatial buffering. In spatial buffering, potassium ions enter
astrocytes and travel through the astrocyte syncytium (astrocytes can be coupled to one
another via ion-permeable gap junctions) to a region where potassium efflux from
astrocytes is favored. When there is a region of increased [K+]o, potassium ions are driven
into astrocytes. This depolarization propagates to other astrocytes via gap junctions. In
regions where [K+]o is low, the driving force (Vm-EK) causes K+ to flow out of the cell.
17

This redistribution of extracellular potassium is dependent on the efficiency of coupling
between astrocytes, unlike the net influx form of potassium buffering.

1.3.1.4 Role of Astrocytes in Glutamate Homeostasis

The role of the astrocyte is certainly not restricted only to ion buffering. Astrocytes
also play a critical role in neurotransmitter uptake, particularly that of glutamate which can
be excitotoxic at high concentrations. This is particularly important under circumstances
of high frequency stimulation in which neurotransmitters can “spill over” from the synapse
and activate extrasynaptic glutamate receptors. In some cases (but not all), extrasynaptic
glutamate can be neurotoxic and it is associated with neurodegenerative diseases. For
example, in ischemia, reduced cerebral blood flow leads to ATP depletion which in turn
inhibits the Na+/K+ ATPase, thus inducing excessive depolarization of neurons and
subsequent calcium toxicity (i.e. via activation of proteases and induction of apoptosis).
Excessive calcium entry into neurons also feeds the cycle by promoting the release of the
excitatory neurotransmitter glutamate. In normal conditions, astrocytes regulate
extracellular glutamate concentrations by taking up glutamate via EAAT (EAAT/GLAST1 and EAAT2/GLT). These proteins are transporters that mediate the influx of sodium,
protons, and glutamate as well as the efflux of potassium. Relevant to the field of
psychostimulant abuse, cocaine self-administration has been shown to downregulate GLT1 expression and functional activity as well as system xc- expression and functional activity.
Administration of the β-lactam antibiotic ceftriaxone restored expression of GLT-1 and
attenuated cue- or cocaine-induced reinstatement of drug seeking behavior (Knackstedt et
al., 2010). Inhibition of the Na+/K+ ATPase during ischemia causes the gradient used for
cotransporting the molecule of glutamate to collapse and results in an inability of astrocytes
to take up extracellular glutamate. The cystine-glutamate antiporter is also upregulated
during ischemia, which contributes to glutamate release from astrocytes. Impaired
glutamate homeostasis such as that observed in ischemia results in excitotoxicity at
synaptic sites and extrasynaptic sites, resulting from increases in the calcium permeability
of neurons, mediated primarily by the NMDA receptors. Activation of extrasynaptic
NMDA receptors by glutamate overflow from astrocytes generates electrophysiological
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events known as slow inward currents (SICs). These currents can be distinguished from
sEPSCs by their much slower kinetics (both rise and decay kinetics) that can be modeled
using a single exponential function during the decay phase. These SICs, despite being
mediated primarily by extrasynaptic glutamate receptors (Pál, 2015), are essential for
modulation of firing in the pendunculopontine nucleus (Kovács and Pál, 2017). Therefore,
the notion that extrasynaptic glutamate activity is only associated with pathological
conditions (i.e. apoptosis) is not universally true. These SICs are associated with many
functions, including synchronization of neuronal circuits (Fellin et al., 2004).

Apart from the excitatory amino acid transporters, another transporter alters
extracellular glutamate concentration. This transporter, known as system xc- mediates
inward transport of cystine and outward transport of glutamate. Cystine is a necessary
component of the antioxidant compound glutathione while glutamate is an excitatory
amino acid neurotransmitter. System xc- is particularly enriched in glia, both microglia and
astrocytes (Bridges et al., 2012). System xc- plays a role in relapse to cocaine seeking
behavior: during withdrawal from a cocaine self-administration paradigm, extracellular
glutamate levels decrease, in line with a decrease in the expression of xc-. Thus, transport
by xc- decreases after withdrawal and restoring the function of xc- after withdrawal (using
N-acetylcysteine, a cystine prodrug) can inhibit the reinstatement of cocaine-seeking
behavior by a priming injection of cocaine. The increase in glutamate mediated by system
xc- is thought to activate presynaptic group II metabotropic glutamate (Gi/o-coupled)
receptors which decrease glutamate release and counter reinstatement behavior presumably
by inhibiting glutamatergic afferents from the prefrontal cortex. Synaptic release of
glutamate is associated with the reinstatement of drug-seeking behavior, and therefore
stimulation of these metabotropic glutamate receptors by xc- decreases reinstatement of
drug-seeking behavior (Baker et al., 2003). Transport by amino acid transporters is not the
only proposed mechanism by which astrocytes regulate extracellular glutamate
concentrations. Briefly, the gliotransmitter hypothesis posits that astrocytes can release
neurotransmitters in response to stimuli from neurons. In the sections that follow, the
gliotransmitter hypothesis will be discussed as a proposed mechanism by which astrocytes
release glutamate. Moreover, astrocytes take up more than just glutamate. They also take
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up GABA, adenosine (Boison et al., 2010), and glycine. Discussion of these other
neurotransmitters is beyond the scope of this thesis, but there is a great amount of literature
discussing these other neurotransmitters (Boison et al., 2010; Schousboe, 2003). Moreover,
there are several excellent reviews summarizing glutamate homeostasis by astrocytes
(Rose et al., 2017; Anderson and Swanson, 2000; Hertz et al., 1999; Kalivas, 2009).

1.3.1.5 Astrocyte Morphology

Astrocytes in vivo generally demonstrate a stellate morphology when stained with
antibodies for glial fibrillary acidic protein (GFAP), a common marker for astrocytes
(Figure 1.2). The cell body of the astrocyte is generally quite small and the majority of the
astrocyte surface area is made up of long ramifications on which there are a large number
of finer processes. These long ramifications are typically visible in brain tissue
immunostained for GFAP. However, GFAP is expressed heterogeneously among
astrocytes, and moreover, is not found in the fine processes of astrocytes (Verkhratsky and
Nedergaard, 2018). This constitutes a critical limitation of utilizing GFAP as a marker to
visualize astrocytes; up to 95% of the volume contained by an astrocyte is localized in the
peripheral processes (Shigetomi et al., 2013). Thousands of these extremely fine astrocytic
processes therefore contribute to the bulk of the volume of astrocytes. Several approaches
have been employed to view the finer processes of astrocytes that form the perisynaptic
and endfoot domains of the astrocytes including iontophoresis with Lucifer Yellow (Moye
et al., 2019) and genetically encoded fluorescent proteins targeted to the plasma membrane
rather than the cytosol (Testen et al., 2020). These approaches reveal a “cloud” of fine
astrocytic processes that extend from the main processes of astrocytes. Such processes
contain calcium microdomains that are highly relevant to studies of astrocyte physiology
(Shigetomi et al., 2013). Many of these fine processes are often called perisynaptic
astrocytic processes (PAPs) due to their extremely close proximity to the postsynaptic
density and the presynaptic terminals of neurons.

A key distinction between astrocytes in vivo and astrocytes in monoculture is that
astrocytes in culture do not normally possess the same stellate morphology. Astrocytes in
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culture are generally flat and polygonal (Figure 1.3). They can be induced to take on a
stellate morphology by adding cAMP to the culture media, but this process of stellation
does not resemble that which occurs during development (Schiweck et al., 2018).
Astrocytes in culture also take on a more stellate morphology in the presence of dopamine
(Galloway et al., 2018), possibly via cAMP synthesis induced by D1 receptor activation. It
is possible to replicate the morphology seen in vivo in culture, complete with fine processes
that possess calcium transients. This can be achieved by co-culture with neurons with
added heparin-binding epidermal growth factor or in cultures containing heparin-binding
epidermal growth factor (HBEGF) and neurobasal medium (media derived from a culture
of neurons); These astrocytes demonstrated stellate morphology (Wolfes et al., 2017).
Moreover, when media is supplemented with HBEGF, astrocytes demonstrate calcium
transients (Morita et al., 2003).

Like their microglial counterparts, astrocytes can enter a “reactive” state
characterized by several phenotypic characteristics. This “reactive” state is just as nebulous
as it is in microglia (in which reactive microglia were previously classified as M1 or M2),
and classification of single cells beyond reactive and non-reactive may not be possible
without rigorous transcriptomic analysis, however, at least one review posits two distinct
phenotypes of reactive astrocytes (Liddelow and Barres, 2017). The protein GFAP has long
been utilized as a marker indicating astrocyte reactivity. Part of the reason for why GFAP
has been utilized as a marker for reactivity is that astrocytes were thought to be highly
proliferative in the reactive state and indeed in some pathological states, there is dramatic
upregulation of GFAP. In fact, astrocytes do not exhibit such extreme proliferative activity,
and there is only a modest increase in proliferation after severe physical injury (i.e. a stab
wound). Paralleling the classification of reactive microglia, an A1 and A2 type of reactive
astrocyte have been proposed. The A1 astrocytes typically express pro-inflammatory
molecules such as TNFα and IL-1β while the A2 astrocytes are immunosuppressant and
express genes such as Arg1 and Fzd1. Ischemia in particular induces polarization to the A2
state in which neurotrophic factors are synthesized while inflammatory insults induce
polarization to the A1 state. Therefore, the A2 state parallels the M2 state of microglia (by
serving reparative functions) while the A1 state parallels the M1 state of microglia (by
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serving inflammatory functions). In reality, this polarization may be an extreme
oversimplification; The M1/M2 polarization of microglia has been called into question,
and thus, it is plausible that the A1/A2 polarization of astrocytes may also be problematic
(Ransohoff, 2016). Thus, just as in microglia, the fate of the A1/A2 argument will rely on
results from single-cell RNASeq (transcriptomic) analyses.
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Figure 1.2 A max intensity projection of rat prefrontal cortex tissue stained for GFAP
(red), an astrocytic marker and NeuN (blue), a neuronal marker, viewed with a confocal
microscope. Astrocytes demonstrate a stellate morphology in vivo. Note that only a
fraction of astrocytes in the field are stained with anti-GFAP antibody. Image taken by
Richik Neogi.

Figure 1.3 Astrocytes in culture take on a distinct polygonal morphology. Here tdTomato
was expressed under the GFAP promoter (image taken by Surya Aryal, reproduced with
permission)
1.3.2 Astrocytic Calcium
Calcium is a unique ion in living systems in that it is also a second messenger.
While other ions like sodium and potassium exert their effects on a cell primarily via an
electrochemical gradient, calcium acts as a direct transducer of cell signaling. Intracellular
calcium concentration varies spatially and temporally in a typical living cell; analysis of
such calcium transients has become a field in and of itself. Initial studies of astrocytic
calcium transients involved bulk loading calcium-sensitive, membrane permeable dyes or
patch dialysis of calcium-sensitive dyes (Russell, 2011). These approaches do not allow
for visualization of the entire astrocyte and come with their own problems that limit their
use when analyzing physiologically relevant intracellular calcium signaling. The
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introduction of genetically encoded calcium indicators (GECI) revolutionized the field of
astrocyte physiology because these indicators can be expressed throughout the astrocyte in
different compartments (plasma membrane, cytoplasm, endoplasmic reticulum) which
allows for visualization of calcium activity in fine astrocytic processes (Tong et al., 2012).
Introduction of a GECI to a live animal entails surgery and injection of a viral vector
carrying the GECI gene alongside a promoter (GFAP and GfABC1D are two documented
promoters for successful expression in astrocytes) directly into brain parenchyma. Since
the GECI itself is fluorescent, there is no need to employ a reporter to indicate successful
transfection. This technique is extraordinarily useful because it not only allows for imaging
in brain slices, but also in vivo imaging. The Lck-GCaMP3 transgene targets the GECI
GCaMP3 specifically to the plasma membrane. Using an AAV2/5 vector, Shigetomi and
coworkers (Shigetomi et al., 2013) successfully achieved hippocampal expression of LckGCaMP3 and cyto-GCaMP3. The Lck-GCaMP3 animals, in particular, revealed the
presence of calcium microdomains in the fine astrocytic processes that previously could
not be effectively visualized. The Lck-GCaMP3 animals expressed GCaMP3 in a “cloud”
surrounding the astrocyte soma whereas the cyto-GCaMP3 animals expressed GCaMP3 in
a more traditional fashion (similar but not identical to that revealed by GFAP IHC). Both
were expressed in the entire astrocytic territory. Analysis of calcium activity using GECIs
and the calcium indicator Fluo-4AM revealed that the GECIs revealed a greater number of
calcium events than the organic calcium indicator.

Calcium transients in astrocytes are not simply epiphenomena of astrocyte
physiology; they play a direct role in brain function. The gliotransmitter hypothesis posits
that astrocytes can release substances that can influence neurotransmission; this hypothesis
will be the subject of the next section. Another function of calcium in astrocytes is to
promote vasodilation of cerebral vasculature via activation of the calcium-dependent
phospholipase A2 (cPLA2) which releases arachidonic acid from membranes. This
arachidonic acid is processed to prostaglandins by cyclooxygenase. Prostaglandins dilate
vasculature. It was demonstrated that stimulation of Gq-coupled metabotropic glutamate
receptors releases prostaglandin and is also associated with vasodilation (Zonta et al.,
2003), although there is some evidence that astrocytic calcium signaling induced by Gq is
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too slow to account for stimulus-induced vasodilation and that mice lacking the gene for
the major inositol triphosphate receptor mediating calcium release from the ER (IP 3R2)
still exhibit stimulus-induced vasodilation (Nizar et al., 2013).

In astrocytes, calcium can enter the cytosol from three different compartments. It
can enter through the plasma membrane by calcium channels driven by the electrochemical
gradient between the cytosol and the extracellular fluid, it can enter by release from the
endoplasmic reticulum via inositol triphosphate (IP3R) or ryanodine receptors (RyR), or it
can be released from the mitochondria, particularly when the cell is apoptotic. A fourth
form of calcium entry can be mediated by connections with other astrocytes (through gap
junctions).

Astrocytes express a variety of calcium channels. In addition to channels such as
Orai, which serve to replenish intracellular (endoplasmic reticulum) stores of calcium,
astrocytes also express voltage-gated calcium channels (VGCCs). Voltage-gated calcium
channels can be divided into four classes based on electrophysiological and
pharmacological properties. The L-type calcium channel has been proposed to promote the
“reactive” state of astrocytes, and indeed LPS-induced reactivity is associated with a
proportionate increase in Cav1.2 expression (Cheli et al., 2016). However, the distribution
of VGCCs in astrocytes is not uniform across all brain regions. Ligand-gated calcium
channels such as the P2X receptors also can plausibly mediate calcium entry into
astrocytes. The P2X7 receptor, activated by high concentrations of ATP, can mediate proinflammatory functions of astrocytes (Panenka et al., 2001) and moreover, activation of
glial P2X7 receptors can modulate synaptic activity in the hippocampus (Khan et al., 2019).
The subject of ion channels on astrocytes has been reviewed in detail elsewhere
(Verkhratsky and Steinhäuser, 2000). The form of calcium entry that has been supported
by the largest amount of evidence, however, is that mediated by release from the
endoplasmic reticulum.

Activation of Gq coupled GPCRs initiates an intracellular cascade that
results in the release of inositol triphosphate (IP3) and diacylglycerol (DAG) from
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phospholipids at the plasma membrane via the action of phospholipase Cβ. The second
messenger IP3 then activates IP3 receptors (IP3Rs) located in the membrane of the
endoplasmic reticulum, resulting in the release of calcium from intracellular stores.
Activation of a wide variety of Gq coupled receptors can initiate calcium activity in
astrocytes including glutamate (Sun et al., 2013), GABAB (Mariotti et al., 2016), dopamine
D1 (Liu et al., 2009), and P2Y (Gallagher and Salter, 2003) receptors. Depending on spatial
and temporal localization, ligands for these receptors can have differential effects on
calcium transients. For example, the P2Y2 receptor promotes more rapidly traveling
calcium waves than the P2Y1 receptor, however the nucleotidase apyrase blocks the
calcium waves produced by P2Y2 receptor activation, but enhances those produced by
P2Y1 receptor activation (Gallagher and Salter, 2003). The specific isoform of the IP3R
that is associated with calcium transients in astrocytes has been proposed to be IP3R2
(Petravicz et al., 2014). Experiments by this group in which IP3R2 was knocked out
suggested that Gq-mediated calcium signaling was abolished. Indeed, knockout mice
(IP3R2 -/-) survive to maturity and there was a significant reduction in the frequency,
amplitude, and duration of somatic calcium transients (Srinivasan et al., 2015). However,
there was a much less pronounced effect in the processes of astrocytes, which constitute
the bulk of the volume contained by astrocytes. The frequency of calcium transients was
not significantly reduced. The duration of calcium transients in the processes was increased
in IP3R2 (-/-) mice and the amplitude was significantly decreased. Knockout of IP 3R2 did
not decrease the mean fluorescence of averaged traces compared to WT mice. The
contribution of transmembrane calcium flux was quantitated using calcium-free buffer – it
was found that calcium-free buffer abolished calcium waves and reduced the basal intensity
of calcium signals. It is therefore plausible that transmembrane flux of calcium plays a role
in calcium transients, perhaps those mediated by the TRPA1 channel (Shigetomi et al.,
2011).

However, IP3R2 knockout could not abolish calcium transients in the peripheral
processes evoked by endothelin, a ligand for a Gq-coupled receptor. It was observed that
only somatic calcium fluctuations mediated by the endothelin receptor could be abolished.
In live unanesthetized animals, it was observed that the frequency of calcium events in
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microdomains (located in the processes of astrocytes primarily) was slightly but
significantly reduced, the amplitude was increased, and the duration of these calcium
events was unaffected by IP3R2 knockout (Srinivasan et al., 2015).

Thus, there is robust evidence that intracellular calcium transients occur in
astrocytes, even with astrocytes in physiological conditions. Both GECIs and calciumsensitive dyes can detect these calcium transients, but GECIs do so more effectively
because they reach all parts of the astrocytes, including the fine processes. The precise
function of these transients in the cell is currently unknown; whether these calcium
transients are responsible for the release of gliotransmitters is a matter of debate in the
field, with one camp insisting that gliotransmitter release occurs in vivo (Savtchouk and
Volterra, 2018) and the other insisting that it does not occur in physiological conditions
(Fiacco and McCarthy, 2018).
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CHAPTER 2. THE SIGMA-1 RECEPTOR
2.1 Molecular Biology and History of the Sigma-1 Receptor
The sigma receptors were initially characterized as novel subtypes of the opioid
receptor family based on studies that revealed the existence of multiple subtypes of opioid
receptors in the spinal dog (Martin et al., 1976). In these studies, morphine was
characterized as the prototypical µ-opioid receptor agonist, ketocyclazocine as the
prototypical κ-opioid agonist, and the benzomorphan SKF-10,047 as the prototypical σreceptor agonist. It was later determined that SKF-10,047 binds to sites in the guinea pig
brain that are not accessible to the potent opioid ligand etorphine, and that this binding
could not be occluded by the opioid antagonist naltrexone (Su, 1982). Thus, the “σ-opioid
receptor” was renamed the σ-receptor (Su et al., 1988).

The sigma-1 receptor (herein referred to as the S1R) was first successfully cloned
in 1996 (Hanner et al., 1996). The corresponding mammalian open reading frame encodes
a protein of mass 25.3 kDa with at least one transmembrane segment. The primary structure
of the protein contains a putative endoplasmic reticulum retention signal (WAVGRR), and
shares sequence homology (67% sequence homology) with a fungal C8-C7 sterol
isomerase, but does not share sequence homology with any other known mammalian
protein (Moebius et al., 1997).

The structure of the S1R has been the subject of debate since its discovery.
Computational algorithms predict the presence of two to three transmembrane domains
(Bolshakova et al., 2016), and some experimental evidence suggests the presence of two
transmembrane domains (Aydar et al., 2002; Mori et al., 2013). In the study by Aydar and
coworkers, GFP was fused either to the C-terminus or the N-terminus. In Xenopus oocytes,
the fluorescence was localized towards the cytoplasmic face of the plasma membrane for
both constructs. This suggests the existence of an even number (i.e. two) of transmembrane
segments, as the constructs would differ in terms of fluorescence localization if there were
an odd number of transmembrane segments. Nevertheless, the x-ray crystallographic
structure of the human S1R reveals an assembly of three protomers, each with a single
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transmembrane domain; this directly contradicts the findings suggesting two
transmembrane domains (Schmidt et al., 2016).

2.2 Sigma-1 Receptor Ligands
The S1R is a unique receptor in that its mode of signal transduction does not rely
on commonly known signal transduction cascades (i.e. those mediated by G-proteins or
receptor tyrosine kinases). Rather, its “activity” is characterized by association with various
partner proteins upon binding of a ligand. This has led to the classification of the S1R as a
“ligand-regulated non-ATP binding membrane-bound chaperone protein (Chu and Ruoho,
2016).” Moreover, ligands for the sigma-1 receptor are structurally diverse (Figure 1.1 and
Figure 1.2)

Helices in the C-terminal region of the S1R are responsible for interaction with
binding immunoglobulin protein (BiP), and it is thought that binding of ligand to the
receptor alters the ability of the S1R to form oligomers (Gromek et al., 2014) via a GXXXG
motif at the C-terminus. Before addressing whether certain ligands are agonists,
antagonists, or inverse agonists, it is important to determine the structural requirements for
a compound to be a ligand of the S1R.

A triple-mutant S1R with alanine substitutions at L105, L106, and S93
demonstrated markedly reduced binding to NE-100 as did a mutant with a phenylalanine
substitution at Y103 and an alanine substitution at S93 also demonstrated similarly reduced
binding. Interestingly, the triple-mutant S1R did not demonstrate reduced affinity for the
S1R agonist (+)-pentazocine (Yamamoto et al., 1999), suggesting differences in the
binding requirements for agonists (pentazocine) and antagonists (NE-100).

With the exception of the cholesterol-based ligands of the S1R (which bind to a
distinct site separate from other ligands), all known S1R ligands possess a basic nitrogen
atom that is critical for interaction with the S1R. Removal of the nitrogen atom from
phenalkylpiperidine derivatives abolished S1R binding (Ablordeppey et al., 2000). Indeed,
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the presence of a basic nitrogen atom flanked by two longer hydrophobic moieties has been
termed the minimal S1R-binding pharmacophore (Schmidt et al., 2018). The notion that a
basic nitrogen atom is critical for ligand binding was confirmed when cells treated with the
crosslinking reagent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) expressed
dramatically reduced affinity for radiolabeled haloperidol and radiolabeled pentazocine. In
this context, crosslinking reagents are those that facilitate peptide bond formation between
a sidechain carboxyl group and a free amino group. These findings were corroborated by
the observation that the S1R mutants D126G and E172G demonstrated only 9% and 3% of
the binding to [3H]haloperidol relative to the wild-type control (Seth et al., 2001). In fact,
both agonists and antagonists of S1R require the presence of E172, as revealed by an x-ray
crystallography study assessing the pose and interactions with the S1R of NE-100,
haloperidol, and (+)-pentazocine (Schmidt et al., 2018). However, antagonists and agonists
differ in terms of their binding to other regions of the S1R. Per the minimal S1R-binding
pharmacophore, antagonists take on a linear pose in the binding site with the primary
(longer) hydrophobic arm pointed between α-helix 4 (α4) and α-helix 5 (α5). The shorter
hydrophobic arm of the antagonist occupies the space near D126. In contrast, for the
agonist (+)-pentazocine (and likely for all S1R agonists containing a basic nitrogen),
binding forces α4 away from α5. Moreover, S1R agonists generally have a nonlinear
structure. Thus, in the antagonist-bound state, α4 adopts a similar position to that of the
ligand-free S1R. In the agonist-bound state, S1R must undergo a conformational change to
prevent steric clash with the ligand. The authors verified that other agonists bind in this
manner by docking PRE-084 to S1R, indicating that this conformational change is required
for broader efficacy of all S1R agonists. In kinetic experiments measuring the on and off
rate of (+)-pentazocine and haloperidol, it was determined that there was a rate-limiting
step that was ligand-independent, meaning that for binding to occur, S1R must adopt a
proper conformation. Through MD simulation experiments, it was found that binding
pathway requires two conformational changes in the structure of S1R, independent of the
ligand. These states were reversible, suggesting that binding is stochastic; in order for an
agonist to bind, the receptor must occupy a certain conformational state.
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The S-(+) isomer of methamphetamine is a ligand at the S1R with an affinity
comparable to that of cocaine (2 µM in the mouse brain in competition with pentazocine
for cocaine and 2.16 µM in the rat brain in competition with pentazocine for
methamphetamine). There is conflicting data regarding whether methamphetamine is an
agonist or an inverse agonist at the sigma-1 receptors. Agonists of the S1R normally induce
dissociation of S1R from binding of immunoglobulin (BiP). Methamphetamine increased
the association of BiP with S1R, as demonstrated by co-immunoprecipitation experiments,
although this finding failed to reach significance (p > 0.05) while (+)-pentazocine and PRE084 significantly induced dissociation of BiP from S1R (Hayashi and Su, 2007).
Interestingly, cocaine did not significantly alter the association of S1R with BiP either,
suggesting that this assay may not be able to unambiguously distinguish weak agonists
from antagonists. Thus, the identity of various ligands as agonists or antagonists is still up
for debate, as these results clearly show that some agonists do not dissociate S1R from BiP
while others do. The previously cited affinities of methamphetamine and cocaine for the
S1R are near to those reached in physiologically relevant cocaine or methamphetamine
administration paradigms (Yasui and Su, 2016). Many of the behavioral effects of cocaine
(i.e. cocaine-induced CPP) are attenuated by administration of S1R antagonists such as
NE-100 and BD-1047 (Romieu et al., 2001). Similarly, administration of MS-377, a S1R
antagonist, attenuates the development of locomotor sensitization to methamphetamine
(Takahashi et al., 2000). There is however, some conflicting data on whether it is an agonist
or an inverse agonist for S1R based on cellular data. Methamphetamine behaves as a an
S1R agonist behaviorally while there is conflicting evidence for its actions at the S1R
receptor at a molecular and cellular level.
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Figure 2.1 Sigma-1 receptor agonists are structurally diverse; most possess nonlinear
structures
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Figure 2.2 Sigma-1 receptor antagonists possess a more linear structure than agonists
2.3 Sigma-1 Receptor and DA Signaling
Given that two major psychostimulants (METH and cocaine) are both ligands of
the S1R, one can speculate that the effects at the S1R could alter dopamine receptor
signaling or uptake of dopamine by DAT since the S1R is known to interact with GPCRs
(Kim et al., 2010) and many other client proteins. Indeed, BRET experiments in HEK293T
cells suggest that S1R forms a heteromer with the D1 dopamine receptor and the agonist-
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bound form of S1R stabilizes the outward-facing conformation of dDAT, enhancing
binding of cocaine in the process (Hong et al., 2017).

That the S1R interacts with DAT is particularly relevant to mechanisms of
psychostimulant action, since two major psychostimulants, cocaine and methamphetamine,
are ligands of the S1R as well as DAT. In rat brain tissue, the sigma-1 receptor agonists
PRE-084 and (+)-pentazocine increased the Bmax of [3H]WIN35428 (a DAT inhibitor)
without altering Ki and both drugs also increased the Vmax of dopamine transport by DAT
in low sodium conditions (conditions unfavorable towards inward transport by DAT). It
was also shown in HEK293 cells transfected with dDAT that S1R forms a heteromer with
DAT, much like the S1R does with D1 receptors. When proteins change conformation,
sometimes cysteine residues become exposed to the extracellular milieu. It is possible to
manipulate this change in accessibility using a cysteine accessibility assay. In this assay,
when a drug is added, the conformation of the protein changes in a way that exposes
cysteine residues to a thiol-reactive reagent. It was found that PRE-084, only in the
presence of cocaine, increased C306 accessibility. This increase was abolished by
treatment with a selective S1R antagonist (Hong et al., 2017). This study also recapitulated
the idea that S1R forms higher order oligomers upon treatment with antagonists and can
only interact with DAT in the form of lower order S1R oligomers (dimers and monomers).

Some studies suggest that activation of the sigma-1 receptor during exposure to
methamphetamine opposes the behavioral and cellular effects of METH such as locomotor
sensitization and METH-mediated dopamine efflux. Treatment with PRE-084, a S1R
agonist, or upregulation of the S1R during exposure to methamphetamine in the bath
inhibits METH-stimulated firing activity in dopaminergic neurons. Moreover, treatment
with 1 µM PRE-084 decreased METH-mediated dopamine efflux in vivo and in vitro while
BD1063 had no effect. The study found that S1R colocalizes with DAT at the plasma
membrane, and its association with DAT is increased when METH is present in the bath
(Sambo et al., 2017). That S1R is found to be localized at the plasma membrane associated
with DAT and that METH alone produced no change in the localization provides an
argument against the assumption that METH is an inverse agonist at S1R, since an inverse
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agonist would increase the number of higher-order (DAT unassociated) oligomers which
in turn would localize at the ER. Some studies have suggested that intracellular calcium is
necessary for dopamine efflux induced by AMP via DAT as well as inward currents
mediated by AMP (Gnegy et al., 2004). Indeed, AMP can increase [Ca2+]i in a DATdependent manner. This increase in intracellular calcium could be blocked by depleting
calcium in the ER using thapsigargin, suggesting that the increase in calcium is not due to
transmembrane flux, but rather due to release from the ER, although there is evidence to
suggest that the increase in intracellular calcium was only observed in the presence of
extracellular calcium (Mundorf et al., 1999). In the work by Sambo and coworkers, neurons
either expressing GCaMP6f or loaded with Fura-2-AM were assessed for calcium activity
in the presence of METH and/or PRE-084. It was observed that METH alone increased
intracellular calcium and this increase could be blocked by the DAT inhibitor nomifensine.
This increase could also be blocked by the S1R agonist PRE-084. This study also revealed
that PRE-084 attenuated behavioral responses (ICSS, CPP, and locomotor activity) to
methamphetamine administered by the experimenter (Sambo et al., 2017), although the
S1R antagonist BD-1063 also attenuated these responses. Interestingly, a previous study
examining the effects of S1R agonists on methamphetamine-induced behavior found that
the S1R agonist SA4503 attenuated radiolabeled dopamine efflux, yet it potentiated some
behaviors associated with methamphetamine such as those during drug-discriminatory
tasks and also attenuated others such as locomotor activation. However, S1R antagonists
BD1047 and BD1063 had no effect on radiolabeled dopamine efflux (Rodvelt et al., 2011).

The S1R forms oligomers with several GPCRs such as the mu-opioid receptor (Kim
et al., 2010) and modulates the activity of the GPCR. It has been demonstrated that the D1
dopamine receptor also interacts with S1R and S1R interaction with D1R can modulate the
activity of the D1R. Agonists at the S1R can enhance PKA activation in rat synaptosomal
preparation (from the prelimbic cortex) through the D1R in the presence of a selective D1R
agonist. This effect was clearly mediated by the S1R because it was abolished by
incubation with a S1R antagonist. The S1R agonist enhanced PKA activation in the
presence of a cell-permeable cAMP analog and in the presence of forskolin, an adenylyl
cyclase activator, but did not enhance adenylyl cyclase stimulation by Gs in the presence
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of a dopamine D1 receptor agonist. This suggests that S1R could act somewhere
downstream of the receptor itself to enhance PKA activation. This increase in PKA
activation by S1R agonist could be blocked by incubation with the PKC inhibitor
chelerythrine as well as incubation of synaptosomes in EGTA-containing buffer,
suggesting that PKC and calcium mediate the effect on PKA activation. Moreover,
blockade of voltage-gated calcium channels also abolished the effect of S1R agonist on
PKA activation, suggesting that the source of this calcium is transmembrane flux. It was
demonstrated that PKC is upstream of the increase in intrasynaptosomal calcium, and that
chelerythrine abolished the increase in calcium concentration. Incubation with the ER
calcium-depleting agent thapsigargin had no effect on the increase in intrasynaptosomal
calcium mediated by S1R activation (Fu et al., 2010). Interestingly, PKC in astrocytes has
been implicated in mediating long-lasting behavioral sensitization induced by
methamphetamine. Moreover, incubation of cultures with 10 µM methamphetamine
(within the range considered “physiological”) increased stellation that could be partially
abolished by treatment with a PKC inhibitor. Similarly, incubation with this concentration
of methamphetamine also increased GFAP immunoreactivity and intracellular calcium
activity evoked by 10 µM of dopamine and glutamate (Narita et al., 2005).

To investigate the effects of the S1R-D1 receptor action in cocaine administration,
Navarro and colleagues utilized a variety of techniques to demonstrate the existence of a
D1-S1R heterooligomer and assessed cocaine’s effects on this oligomer (Navarro et al.,
2010). In HEK293T cells, BRET (between σ1-YFP and D1-Rluc) was utilized to determine
the existence of heterooligomers and indeed it was determined that a heterooligomer
between the S1R and D1 receptor exists in cell culture. Moreover, treatment with cocaine
induced translocation of S1R to the plasma membrane and colocalization with the D1
receptor. Utilizing a D1-YFP and D1-Rluc pair, the BRET signal was reduced dosedependently in the presence of cocaine, suggesting that S1R receptor activation disrupts
D1 receptor homodimers. In CHO cells, cocaine robustly enhanced cAMP accumulation
induced by treatment with a selective D1 receptor agonist. When CHO cells were treated
with cocaine alone, there was no increase in cAMP accumulation, however, when they
were treated with cocaine and SKF-81297, a D1 receptor agonist, there was potentiation of
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cAMP accumulation. Similarly, D1 receptor-mediated phosphorylation of ERK1/2 by
activation via SKF-81297 could be blocked by administration of PD-144,418, an S1R
antagonist. Cocaine and PRE-084 could increase the phosphorylation of ERK1/2 in the
absence of a D1 receptor ligand. However, in combination with a D1 receptor agonist (SKF81297), cocaine and PRE-084 counteracted the increase in ERK1/2 phosphorylation by
SKF-81297. The results from the cAMP accumulation and ERK1/2 phosphorylation
experiments were recapitulated in slices from mouse striatum; incubation with either the
D1 receptor agonist or cocaine increased phosphorylation of ERK1/2. Moreover, in striatal
slices from S1R knockout animals, cocaine was unable to induce ERK1/2 phosphorylation.
Therefore, when present in this heterooligomeric form with the D1 receptor, the sigma-1
receptor can phosphorylate ERK1/2 alone, but when both a sigma-1 receptor agonist and a
D1 receptor agonist are present, ERK1/2 phosphorylation is counteracted, suggesting an
antagonistic interaction between the two receptors. A potential area of further research
would be to observe if these findings can be recapitulated in pure astrocyte culture or
astrocyte-rich cell culture.

The S1R also forms complexes with the dopamine D2 receptor, however in this
case, the S1R turns down signaling via the D2 receptor (Navarro et al., 2013). Like in the
previous report regarding D1 receptors, D2/D3/D4 receptors were fused to Rluc and σ1
receptors to YFP. A significant BRET signal was observed with D2 receptors but not with
D3 or D4 receptors in HEK293T cells. Moreover, after transfection with D2 receptor cDNA,
colocalization between S1R and D2 receptors was detected. In cells expressing both RlucS1R and YFP-S1R, homodimers between S1R protomers were detected via BRET and
heterooligomers of S1R with D2 receptor homodimers were detected as well.
Diheterotetramers (S1R-S1R-D2-D2) were detected using a modified BRET protocol.
Further BRET experiments revealed that activation of the S1R induces changes in the D2D2 homomers and in the S1R-D2 heteromers. In functional assays using CHO cells, it was
determined that cocaine alone does not elicit any changes in D2 receptor signaling, but
there is a small but significant decrease in D2 receptor signaling when cells were pretreated
with cocaine (30 µM) and then treated with increasing concentrations of quinpirole.
Moreover, cocaine significantly decreased the D2-mediated decrease in forskolin37

stimulated cellular cAMP evoked by the D2 receptor agonist quinpirole. This effect was
also observed when PRE-084 was utilized in lieu of cocaine. However, when both
quinpirole and cocaine were incubated with cells at the same time, negative cross-talk was
detected, indicating an antagonistic interaction between the two receptors. It was also
determined that activation of the S1R in the D2-S1R heteromer can induce phosphorylation
of ERK1/2 and that the D2 antagonist raclopride or S1R antagonist PD144418 could inhibit
ERK1/2 phosphorylation. To investigate whether these results could be recapitulated in
mouse striatum, first, a Western blot and coimmunoprecipitation experiment were
conducted. It was found that S1R was detected in WT but not S1R KO mouse striatum and
D2 receptors were expressed in both groups. The coimmunoprecipitation experiments
revealed that the S1R does indeed form stable oligomers with the D2 receptor. A proximity
ligation assay also confirmed that the S1R formed stable oligomers with the D2 receptor
and that these results were not artifacts of detergent solubilization. Moreover, the
antagonistic interaction on ERK1/2 phosphorylation was also observed in mouse striatal
tissue: incubation with both quinpirole and cocaine abolished ERK1/2 phosphorylation,
but when incubated with either compound alone, an increase in ERK1/2 phosphorylation
was observed.

Thus, the sigma-1 receptor interacts directly with both the D1 and D2 receptors. It
has also been suggested that the sigma-2 receptor interacts with the D1 receptor but not the
D2 receptor. While the sigma-2 receptor is beyond the scope of this chapter, it is important
to note that it does interact with the D1 receptor exclusively. Evidence suggests that the
sigma-1 receptor may form a heterotrimeric complex with the sigma-2 and D1 receptors.
When siRNA for the sigma-1 receptor was introduced to HEK293T cell culture (thus
disrupting the heterotrimeric complex), cocaine and an agonist for the sigma-2 receptor
reduced cAMP formation in the presence of a D1 receptor agonist. Conversely, when
siRNA for the sigma-2 receptor was introduced, cocaine potentiated agonist-induced
cAMP formation. In cells lacking the sigma-1 receptor, but expressing D1 receptor and
sigma-2 receptor, cocaine pretreatment potentiated ERK1/2 phosphorylation via a D1
receptor agonist. In cells that expressed the sigma-1 receptor and D1 receptor but not the
sigma-2 receptor, cocaine inhibited ERK1/2 phosphorylation via a D1 receptor agonist.
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Moreover, when all three receptors (sigma-1, sigma-2, and D1) were expressed in cell
culture, there was no effect of cocaine on cAMP accumulation or ERK1/2 phosphorylation,
suggesting an antagonistic interaction between the sigma-1 receptor and sigma-2 receptor
on the D1 receptor. In striatal sections from rats injected acutely or chronically with
cocaine, differences were observed in terms of the number of cells expressing D1-σ1
oligomers or D1-σ2 oligomers. For cocaine-naïve animals, 38.5% of cells expressed D1-σ1
oligomers and 25% of cells expressed D1-σ2 oligomers. In animals acutely treated with
cocaine, the number of both oligomeric complexes (measured by counting puncta) was
increased, but 54% of cells expressed D1-σ1 oligomers and 33% expressed D1-σ2 oligomers.
When animals were treated chronically with cocaine, the number of D1-σ1 oligomeric
complexes and the number of cells expressing D1-σ1 oligomers were restored to that of
cocaine-naïve animals, but the number of D1-σ2 oligomeric complexes remained elevated
and the number of cells expressing D1-σ2 complexes remained approximately the same.
These results suggest that acute administration of cocaine drives increases in primarily the
D1-σ1 oligomers, but chronic administration of cocaine drives an increase in D1-σ2 receptor
oligomers (Aguinaga et al., 2018).

2.4 Physiology of the Sigma-1 Receptor
2.4.1 Sigma-1 Receptor Localization
The sigma-1 receptor is primarily an ER-localized protein. In particular, it is
enriched at the mitochondrial associated membrane (MAM), the junction between
mitochondria and the ER, where it can regulate calcium flux into mitochondria by
associating with IP3 receptors. It forms raft-like microdomains enriched in cholesterol on
the ER and is thought to regulate lipid transport from the ER to the plasma membrane;
treatment with (+)-pentazocine causes these sigma-1 receptor-containing microdomains to
disappear (Hayashi and Su, 2003). In normal, agonist-free conditions, the sigma-1 receptor
at the ER is bound to binding of immunoglobulin protein (BiP), a molecule involved in the
response to unfolded proteins. It was observed in CHO cells that upon calcium depletion
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(by ATP via P2Y receptors, by treatment with thapsigargin, or by treatment with the
calcium chelator BAPTA), the S1R dissociates from BiP and forms complexes with IP3R3.
Treatment with (+)-pentazocine after thapsigargin-mediated calcium depletion increases
the coupling between S1R and IP3R3 (Hayashi and Su, 2007). A previous study suggested
that ankyrin B (particularly the ankyrin 220 isoform), IP3R3, and the S1R associate in the
ER (see Figure 2.3). Treatment with (+)-pentazocine evoked dissociation of S1R from
ankyrin B and presumably IP3R3, since this treatment also caused the S1R to disappear
from the P3L (ER-enriched) fraction and translocate to the plasma membrane (Hayashi and
Su, 2001).

Figure 2.3 Agonists promote the formation of lower order oligomers which can interact
with other protein clients. Inverse agonists and antagonists promote the formation of
higher-order oligomers which represent the inactive state of the receptor (Chu and
Ruoho, 2016). Red circles represent the states that can interact with protein clients while
blue represents the inactive state.
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Figure 2.4 The interaction between IP3R3, the sigma-1 receptor, and ankyrin occurs in the
basal, unstimulated state. Upon sigma-1 receptor binding (blue circle), ankyrin and the
sigma-1 receptor dissociate from IP3R3 and this allosterically potentiates IP3R3,
increasing efflux of calcium. Since IP3 (red circle) concentrations at basal state are not
high enough to stimulate efflux of calcium, there would initially be no calcium release.
Upon addition of the sigma-1 receptor agonist, the IP3R becomes more sensitive to
intracellular IP3 concentration. This may enable the IP3R receptor to become active in
basal state, but evidence suggests that Gq-coupled receptor stimulation is required to fully
observe the potentiating effect of the sigma-1 receptor (Hayashi and Su, 2001). Image
created in Biorender.
Sigma-1 receptor ligands can also regulate the homo-oligomeric status of the S1R
(Chu and Ruoho, 2016). In physiological conditions, the intracellular population of the S1R
is distributed among monomeric and oligomeric states. There is evidence that the S1R may
be constitutively active, based on findings that demonstrated that the sigma-1 receptor can
release inhibition of G-protein mediated signaling; overexpression of the sigma-1 receptor
can increase bradykinin-mediated intracellular calcium release in the absence of agonists
for the bradykinin receptor. Inverse agonists like BD-1063 bias the population S1R towards
higher order oligomers while agonists bias the population of lower order oligomers (Figure
2.3). The dimers are thought to allow S1R to form chaperone complexes, while the
monomers are thought to allow S1R to form chaperone complexes and complexes with
protein partners (Chu and Ruoho, 2016). It was also demonstrated that sigma-1 receptor
agonists can induce translocation of the sigma-1 receptor to focal adhesion contacts at the
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plasma membrane in CHO cells (Mavlyutov and Ruoho, 2007). Interestingly, stabilization
of F-actin filaments dramatically enhanced the number of S1R at the plasma membrane,
suggesting that the actin cytoskeleton may play a role in translocation of the S1R.

2.4.2 Sigma-1 Receptor and IP3 Receptors
As stated in the previous section, the sigma-1 receptor responds to calcium
depletion in the ER by increasing its coupling with IP3R3. Moreover, sigma receptor
agonists induce dissociation of the S1R and IP3R from ankyrin B (Hayashi and Su, 2001).
This dissociation alone was not found to increase cytosolic calcium concentrations,
however, in the presence of an agonist for a Gq-coupled receptor (bradykinin) of thus,
presumably increased IP3 concentrations, various sigma-1 receptor agonists enhanced the
increase in cytosolic calcium (although it has been observed that the sigma-1 receptor
agonist BD-737 alone can increase IP3 synthesis in cardiac myocytes; see Novakova et al.,
1998). In the work by Hayashi and Su in 2001, it was determined that dissociation of
ankyrin from IP3R increased the binding of [3H]IP3, suggesting that sigma-1 receptormediated dissociation of ankyrin from IP3R can potentiate calcium efflux from the ER by
increasing binding of IP3 to IP3R. The potentiation of bradykinin-induced calcium release
was determined to occur in a bell-shaped manner with respect to S1R agonist
concentration, and was unaffected by removing calcium from the bath solution (Hayashi
et al., 2000). Importantly, three different agonists (PRE-084, pentazocine, and
pregnenolone sulfate) of the S1R increased bradykinin-potentiated calcium release from
the ER. The effect of PRE-084 on intracellular calcium was abolished by the S1R
antagonist NE-100 and the effects of the other ligands were abolished by knockdown of
the S1R. In these experiments, no potentiating effect on intracellular IP3 concentration was
observed, although (+)-pentazocine increased the ceiling of bradykinin-induced IP3
formation. Although discussion of the protein chaperone role of the sigma-1 receptor is
beyond the scope of this manuscript, it should be noted that the sigma-1 receptor prevents
proteasomal degradation of the IP3 receptor. Knockdown of the sigma-1 receptor revealed
prominent proteasomal degradation of IP3R3 upon ATP stimulation of P2Y2 receptors
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(Hayashi and Su, 2007). Thus, the sigma-1 receptor modulates IP3R3 at multiple levels. It
can directly enhance activation of IP3R3 and it can also prevent degradation of IP3R3.

2.4.3 Sigma-1 Receptor and Store-Operated Calcium Entry (SOCE)
When intracellular stores of calcium are depleted, STIM1 detects the drop in ER
calcium concentration and translocates to the plasma membrane-ER junction where it binds
to the calcium channel Orai1. To deplete HEK cells of intracellular calcium stores, the cells
were treated with thapsigargin in calcium free media. Subsequently, calcium was added to
the media and intracellular calcium concentration was measured. This technique effectively
measures the degree of SOCE. It was found that in HEK cells transfected with S1R, the
increase in intracellular calcium subsequent to addition of calcium to the media was blunted
compared to cells not expressing S1R. A similar effect was observed in cells treated with
carbachol and ATP (these compounds trigger endogenous depletion of ER calcium). To
investigate whether ligands of S1R can modulate the S1R-mediated effects on SOCE, cells
were treated with the S1R agonist SKF10047 and the S1R antagonist BD-1047. It was
observed that the antagonist enhanced SOCE while the agonist inhibited SOCE in HEK
and CHO cells transfected with S1R. Coimmunoprecipitation assays revealed that S1R
associates with STIM1 and that treatment with a S1R agonist increases this association
while treatment with a S1R antagonist decreases it. Upon calcium depletion, the STIM1S1R complex translocates to the ER-plasma membrane interface, where it associates with
Orai1. The sigma-1 receptor decreases the speed at which this translocation occurs and
additionally inhibits association with Orai1. It was determined that the S1R exerts its
effects via STIM1 rather than via association with Orai1 (Srivats et al., 2016).

2.4.4 Sigma-1 Receptor and the Actin Cytoskeleton
Following the finding that sigma-1 receptor activation mediates dissociation of
IP3R3 from ankyrin (Hayashi and Su, 2001), it was proposed that cocaine may mediate
changes to the spectrin-actin cytoskeleton via the sigma-1 receptor (Su and Hayashi, 2000).
Ankyrin is an adaptor protein that is normally bound to the spectrin component of the actin43

spectrin cytoskeleton. Specifically, spectrin serves as a crosslinker between actin filaments,
forming the mesh that gives the plasma membrane definition. Ankyrin, as an adaptor
protein, connects spectrin to other membrane proteins and cell adhesion molecules. This
dissociation results in increased flux of calcium ions from the ER due to enhanced binding
of IP3 to IP3R3. The dissociation mediated by cocaine as a ligand has been observed to be
persistent for up to two hours, suggesting this dissociation may not be transient in nature.
Calcium can modulate the interaction between spectrin and actin (Tanaka et al., 1991).
Hayashi and Su also proposed that cocaine-mediated modulation of intracellular calcium
due to activation of Gq-coupled D1x receptors may also modulate the cytoskeleton. It was
specifically proposed that these changes in the cytoskeleton can affect the architecture of
dendrites and dendritic spines, but it may be equally plausible that these same changes
occur in astrocytes.

2.5 Distribution of the Sigma-1 Receptor in the Rat NAcc and PrL
2.5.1

Background

The sigma-1 receptor is expressed in many tissues including the brain, heart, lungs,
and liver. It is well known that neurons express the sigma-1 receptor. Previous
immunohistochemical data suggests that the S1R is moderately expressed by neurons and
ependymocytes throughout the brain, including the striatum. However, in this report, there
was no sigma-1 receptor staining within astrocytes (Alonso et al., 2000). In this report,
sigma-1 immunoreactivity detected via electron microscope was punctate and located in
the perikaryal and dendrites of neurons, with a distinct absence of any immunoreactivity
in the axons. Nevertheless, more recent data has come to light suggesting that both neurons
and astrocytes in the striatum express the sigma-1 receptor modestly (Francardo et al.,
2014). If indeed the sigma-1 receptor is expressed in astrocytes, then it is plausible that
sigma-1 receptor agonists can promote morphological alterations by its interactions with
the actin cytoskeleton and IP3R (Hayashi and Su, 2001). Indeed, in vitro and in vivo
treatment with METH in mice increases astrocyte reactivity (indicated by stellation and
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increased GFAP expression). Moreover, addition of METH to astrocyte-neuron cell
cultures enhanced intracellular calcium release evoked by glutamate and dopamine (Narita
et al., 2005). Whether these METH-mediated alterations are dopamine-mediated, S1Rmediated, or both is still an open question in the field.

In order for the S1R to be relevant to astrocytic physiology, it must be expressed
by astrocytes. Given the conflicting literature regarding expression of S1R by astrocytes,
the present experiment was designed to probe the expression of the S1R by astrocytes. The
prelimbic cortex and the nucleus accumbens were selected due to their involvement in
mediating drug-seeking behavior.

2.5.2 Materials and Methods
Male Sprague-Dawley rats weighing between 322 and 566 grams were deeply
anesthetized using ketamine/xylazine/acepromazine and transcardially perfused first with
cold 4% paraformaldehyde (PFA) and cold 1X phosphate-buffered saline (PBS). The
brains were removed and 1 mm thick sections were cut on the vibratome (Leica VT1200)
containing the PFC and nucleus accumbens in 1X PBS. The thick sections were
cryoprotected for two days in 30% sucrose (prepared in 1X PBS). They were then frozen
on the cryostat at -16oC and sliced into 50 µm thick sections. The 50 µm thick slices were
placed into a freezer storage medium consisting of the following: 30% w/v sucrose in a
solution containing 300 mL of ethylene glycol, 300 mL of glycerol, and 300 mL of 1X
PBS.

The 50 µm sections were thawed at 4 degrees Celsius, placed in 15% sucrose (in
1X PBS) for 15 minutes, and then washed in 1X PBS three times for 10 minutes. Two
different primary antibody cocktails were used, one containing 1:1000 rabbit anti-Sigma1
receptor (Abcam, ab53852) and 1:1000 goat anti-GFAP (Abcam, ab53554) while the other
contained 1:1000 mouse anti-NeuN (Novus Biologicals, NBP1-92693) and 1:1000 rabbit
anti-Sigma1 receptor. These two different groups are called Group GSD (GFAP, Sigma-1,
and DAPI) and NS (NeuN and Sigma-1). Both were prepared in an antibody dilution buffer
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containing 3% normal donkey serum in 1X PBS with 0.2% Triton X-100. First, the slices
were blocked in a solution of 10% v/v normal donkey serum and 0.2% Triton X-100 in 1X
PBS for 30 minutes. Subsequently, the primary antibody cocktail was added, and the slices
were allowed to incubate overnight at 4 degrees Celsius. After overnight incubation, the
slices were washed 3x10 minutes in 1X PBS and blocked again using a blocking buffer
serum from the same animal as the host identity of the subsequent secondary antibody. For
slices stained with anti-NeuN, normal goat serum was used while for slices stained with
anti-GFAP, normal donkey serum was used. Donkey anti-goat A647 (Abcam, ab150135),
goat anti-rabbit or goat anti-mouse A405 (Thermo-Fisher, A31553) were used. Slices were
incubated with each secondary antibody for 2 hours at room temperature. After washing
3x10 minutes, the slices were blocked with normal goat serum-containing blocking buffer
and incubated with goat anti-rabbit A594 (Abcam, ab150088) for 2 hours at room
temperature. Slices stained with GFAP were incubated with 2.86 µM DAPI for 10 minutes
and then washed 3x10 minutes with 1X PBS-T (0.2% Triton X-100 in 1X PBS). Slices
strained with NeuN were washed 3x10 minutes with 1X PBS. All slices were then mounted
and coverslipped using Prolong Gold Antifade or Prolong Diamond Antifade.

For image acquisition, the Nikon A1R confocal microscope was used. The pinhole
diameter was set at 1.2 AU for all samples. The general region of interest (prelimbic cortex
or nucleus accumbens) was identified using the 10x (air-immersion) and 20x (waterimmersion) objectives. Initial gain and power settings for each channel are displayed in
Table 2.1. At all times, the gain was 30x higher than the power of the laser. Images were
taken with 4x line averaging at resolution 1024x1024. First a large tiled image was taken
using the 40x objective, then the area of interest was identified and a z-stack with slices
spaced 1 µm apart (ranging from 10-12 µm total per stack) was taken. The resulting ND2
files were saved and imported to NIS-Elements for processing. Background was subtracted
using the rolling ball method and images were deconvolved for 10 iterations using the blind
method of 3D deconvolution. After image acquisition, all slices were visualized using the
10x bright field objective on the AxioScan slide scanner. Slices that did not contain the
nucleus accumbens or the prelimbic cortex were excluded from analysis.
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Table 2.1 The initial gain and power settings utilized to visualize immunostained tissue

HV (gain)

Power

647 nm

90

3

561 nm

90

3

405 nm

150

5

Data analysis was conducted using Fiji ImageJ. First, either DAPI-positive or
NeuN-positive cells were counted using the multi-point tool. For tissue stained with antiGFAP, subsequently, all astrocytes with visible nuclei were counted. The criterion for
inclusion as an astrocyte were: GFAP immunoreactivity must fully or partially surround
the DAPI staining and the identified cells must have two or more visible processes
projecting from them. The criteria for identification as a neuron was simply round NeuN
immunoreactivity. For a cell to be considered positive for the sigma-1 receptor, 3 or more
puncta had to be present within the GFAP/DAPI+ or NeuN+ area. Statistical analysis (two
sample t-tests assuming unequal variance) was conducted in GraphPad Prism. Total cell
count was calculated by counting all cells in a z-stack and dividing by the volume enclosed
by the z-stack. Proportions were calculated by dividing one category in the total cell count
by another.
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2.5.3 Results

Figure 2.5 A maximum intensity projection of a NAcc slice; GFAP (magenta), Sigma1
receptor (yellow), and DAPI (blue). Z-stack thickness: 11 µm.
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Figure 2.6 A maximum intensity projection of a NAcc slice; NeuN (blue) and Sigma1
(yellow)
For total cell count analysis of NAcc slices in group NS there were n = 10 slices
and n = 7 in group GSD included in the analysis. For analysis of PrL slices, in group NS,
there were n = 6 slices and in group GSD, there were n = 6 slices. These slices came from
two animals. The total cell count revealed a significantly greater density of DAPI-positive
cells in the nucleus accumbens versus the prelimbic cortex (p < 0.05) and a significantly
greater density of DAPI-stained cells with sigma-1 receptor immunoreactivity (group
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GSD; p < 0.05) in the nucleus accumbens versus the prelimbic cortex. All total count data
is presented in Figure 2.7. Astrocytes in both the nucleus accumbens and prelimbic cortex
possessed characteristic sigma-1 receptor immunoreactivity in their processes (Figure 2.9).
In NS slices, sigma-1 receptor immunoreactivity was distributed throughout the cytosol
and on the plasma membrane of neuronal cell bodies (Figure 2.10). No significant
differences between regions were found when analyzing the proportion of cells that were
sigma-1 receptor immunoreactive (Figure 2.8). In both the PrL and the NAcc,
approximately 73% of DAPI stained nuclei contained clustered puncta of sigma-1 receptor
immunoreactivity. Interestingly, on average, almost all (97.8%) neurons in both regions
expressed the sigma-1 receptor, while most, but not all (91.2%) GFAP-positive astrocytes
expressed the sigma-1 receptor.

Figure 2.7 A graph showing the total cell counts. Note that the Sigma+ category denotes
sigma-1 receptor-positive cells in GSD slices while Sigma+ (NeuN) denotes cells in NS
slices
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Figure 2.8 A graph showing proportions. Here, the proportion represents the number of
cells positive for type A (i.e. sigma-1 receptor immunoreactivity) out of cells positive for
type B (i.e. DAPI+ cells). No statistically significant differences were noted between
regions.
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Figure 2.9 A maximum-intensity projection image of a single astrocyte in the nucleus
accumbens taken with the 60x oil-immersion objective. Note both perinuclear (blue
indicates DAPI) and peripheral sigma-1 receptor immunoreactivity (yellow) in the
astrocyte (magenta) or on the membrane of its processes.

Figure 2.10 A maximum-intensity projection image of a neuron (blue is NeuN
immunoreactivity) in the nucleus accumbens with sigma-1 receptor immunoreactivity
(yellow) inside the cytosol/nucleus and along the surface of the cell body. Image taken
with the 40x water-immersion objective.
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2.5.4 Discussion
In conclusion, we note that like Francardo and coworkers, there is detectable and
significant sigma-1 receptor density in astrocytes of the striatum, particularly in the nucleus
accumbens. It is possible that the antibody prepared by Alonso and coworkers (Alonso et
al., 2000) does not bind the sigma-1 receptor with high enough avidity (the total binding
strength at every binding site on the antibody) or affinity to detect the levels of expression
within striatal astrocytes. Indeed, they reported low to medium-intensity sigma-1 receptor
immunoreactivity in the striatum, in stark contrasts with results that we and others have
found (Francardo et al., 2014). It may also be possible that the use of a confocal microscope
by ourselves and Francardo et al. permitted greater resolution than the images obtained by
Alonso and coworkers. The source of this discrepancy remains unknown. Nevertheless,
here, we demonstrate conclusively that astrocytes in the nucleus accumbens and the
prelimbic cortex express the sigma-1 receptor.

The increased DAPI+ cell count in the nucleus accumbens versus the prelimbic
cortex suggests a greater cell density in the nucleus accumbens. The greater number of
sigma-1 receptor immunoreactive cells in the nucleus accumbens and prelimbic cortex
versus the number of astrocytes counted suggests that many other cells (including
astrocytes that do not express GFAP) also express the sigma-1 receptor. The increased total
cell count of sigma-1 receptor immunoreactive DAPI-positive cells is not reflected in the
analysis of the proportion of sigma-1 positive cells, suggesting that the increased total
sigma-1 immunoreactive DAPI-positive cell count may simply be a product of increased
cell density in the nucleus accumbens. However, it should be noted that GFAP expression
is highly heterogeneous and that striatal astrocytes typically express less GFAP mRNA
relative to hippocampal astrocytes (Chai et al., 2017). Thus, it is plausible that a subset of
the DAPI-positive, S1R-positive cells are really astrocytes that do not express GFAP.
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There are several limitations to this experiment. First is the fact that the number of
channels on the Nikon A1R in confocal mode limits the number of different antibodies that
can be used on a single slice. Ideally, both NeuN and GFAP would be labelled in the slices
in addition to the Sigma-1 receptor, and the nuclei of NeuN and GFAP-positive cells would
also be visible. However, this could not be accomplished due to the limited number of
channels on the confocal microscope. While it is theoretically plausible to use the goat antimouse A405 antibody in conjunction with the donkey anti-goat A647 and goat anti-rabbit
A594 antibody, this would have meant that DAPI could not be used. Detection of cell
nuclei is important for counting astrocytes, as their convoluted morphology makes it
difficult to distinguish one astrocyte from the other. Second, the small sample size limits
statistical analysis because it is not possible to account for potential animal to animal
differences: only two rats were sacrificed to generate these slices. In order to determine the
influence of animal-to-animal variability on these results, a larger number of animals and
a larger number of sections should have been used.
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CHAPTER 3. SIGMA-1 RECEPTOR-MEDIATED EFFECTS OF
METHAMPHETAMINE IN ACUTE STRIATAL SLICE PREPARATIONS FROM THE
RAT
3.1 Background
From the previous experiment, we have concluded that there is robust expression
of the sigma-1 receptor in both astrocytes and neurons of the nucleus accumbens. The
sigma-1 receptor is involved in mediating dopamine release in the mouse nucleus
accumbens slice preparations. An indirect link between reactive oxygen species (ROS) via
the sigma-1 receptor is suggested to contribute to dopamine release because both
METH+BD-1063 and the antioxidant TEMPOL+METH reduced dopamine efflux relative
to METH alone. It was found that VMAT2 was S-glutathionylated and that this Sglutathionylation can be blocked by incubation with the sigma-1 receptor antagonist BD1063 (Hedges et al., 2018). Glutathionylation impairs VMAT2 function and thus enhances
accumulation of dopamine in the cytosol. Although there is evidence of VMAT2
expression in astrocytes (Petrelli et al., 2018), generation of reactive oxygen species (ROS)
and increased intracellular calcium release via the sigma-1 receptor activation by METH
could have different effects on astrocytes than on neurons. It has already been described in
the literature that extracellular dopamine modulates astrocyte morphology in a
concentration-dependent manner (Galloway et al., 2018). Therefore, it is plausible that
elevated dopamine release via the sigma-1 receptor can induce morphological alterations
in astrocytes.

Since the sigma-1 receptor modulates the actin-spectrin cytoskeleton (Su and
Hayashi, 2001) and intracellular calcium release enhanced by the actions of sigma-1
receptor could potentially affect the interaction between spectrin and actin (Tanaka et al.,
1991), it is also plausible that direct activation of the sigma-1 receptor can modulate the
morphology of astrocytes by directly altering the actin-spectrin cytoskeleton.

In the present experiment, we sought to determine the contribution of the sigma-1
receptor to changes in sigma-1 receptor distribution and astrocytic morphology. Although
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we could not probe the effects of dopamine receptor activation, we were able to do so
indirectly, as treatment with BD-1063 (Hedges et al., 2018) and PRE-084 (Sambo et al.,
2017) have been shown to reduce dopamine release in slice preparation and dopamine
neuron cell culture, respectively.

3.2 Materials and Methods
Two adult male Sprague-Dawley rats were deeply anesthetized with isoflurane and
then decapitated. The brain was sectioned into 300 µm thick slices containing the striatum,
particularly the nucleus accumbens as well as the caudate-putamen. Slices were incubated
in aCSF (in mM: 2 CaCl2, 3 KCl, 1 MgCl2, NaH2PO4 1.25, NaHCO3 26, and d-glucose 10)
until all necessary slices were cut. The slices were transferred to solutions according to
Table 3.1; all solutions were prepared in aCSF. The concentration of PRE-084 used was
derived from Sambo et al., 2017. The concentration for BD-1063 was taken to be a
saturating concentration from Zhang et al., 2017. The concentration of METH used was
calculated from results indicating the physiological mass of methamphetamine per unit
mass of brain tissue derived from experiments in which rats were given 1 mg/kg of
methamphetamine (i.v., Riviére et al., 2000). The slices were incubated for 2 hours at 37
°C before they were removed and placed in 4% paraformaldehyde in 1X PBS. After 3 hours
of fixation, the slices were transferred to 30% sucrose in 1X PBS for cryoprotection and
allowed to cryoprotect until the slices sank in the medium.

Table 3.1 All solutions used to incubate the slices from two different animals

Meth (24.7 μM)

aCSF

BD-1063 (49.5 μM)

300 μm (n = 3 slices) Not collected

PRE-084 (9.9 μM)

300 μm (n = 1 slice)

300 μm (n = 1 slices)

aCSF

300 μm (n = 1 slice)

300 μm (n = 1 slices)
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From the 300 µm slices, 50 µm thick sections were cut on a cryostat (Leica CM
1860) and placed into freezer storage medium. When IHC was conducted, the sections
were thawed at 4 ºC and then transferred to 15% sucrose solution. The slices were then
transferred to 1X PBS and washed 3x10 minutes. They were then blocked in blocking
buffer (10% NDS and 0.2% Triton X-100 in 1X PBS) and then incubated with primary
antibody cocktail [1:1000 polyclonal rabbit anti-Sigma1 (Abcam, ab53852) and 1:1000
polyclonal goat anti-GFAP (Abcam, ab53554) in 3% NDS, 0.2% TX-100, and 1X-PBS]
overnight at 4 ºC.

After incubation with the primary antibodies, the slices were washed 3x10 minutes
with 1X PBS at room temperature. They were then blocked in blocking buffer made from
NGS rather than NDS for 30 minutes. After protecting the slices from light and removing
the blocking buffer, 1:400 polyclonal goat anti-rabbit A594 (buffer composition: 3% NGS
and 0.2% Triton X-100 in 1X PBS; Abcam, ab150088) was added and the slices were
incubated for 2 hours at room temperature. Subsequently, the slices were washed 3x10
minutes with 1X PBS and blocked again with blocking buffer made from NDS. The slices
were incubated with 1:400 polyclonal donkey anti-goat A647 (Abcam, ab150135) for 2
hours. They were then washed 3x10 minutes with 1X PBS and transferred to DAPI working
solution (2.86 µM DAPI in PBS-T consisting of 0.2% TX-100 in 1X PBS). Following
incubation for 10 minutes, the slices were washed 3x10 minutes in PBS-T. They were then
mounted and coverslipped with Prolong Diamond Antifade.

All images were acquired on the Nikon A1R confocal microscope with a pinhole
diameter of 1.2 AU and image resolution of 1024x1024 using a 60x oil-immersion
objective (NA: 1.4) with 4x line averaging. The power of the laser and the gain was set
such that gain was always 30x greater than the power (initial settings were identical to
those displayed in table 2.1). Since some slices contained the nucleus accumbens and others
did not, the images are of areas within the caudate putamen. Large, stitched images of all
the slices can be seen in Figure 3.1 while maximum intensity projection images can be seen
in Figure 3.2.
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Figure 3.1 Large stitched images of striatal tissue; DAPI (blue), anti-Sigma1 receptor
(yellow), and anti-GFAP (purple). Top left: aCSF; top middle: METH; top right: METH
+ BD-1063; bottom left: METH + PRE; bottom right: PRE
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Figure 3.2 Representative images showing the maximum intensity projection of each
slice (z-projection was taken of 6 slices or 6 µm containing the most astrocytes, hence the
differences in background); DAPI (blue), anti-Sigma1 receptor (yellow), and anti-GFAP
(purple). Top left: aCSF; top middle: METH; top right: METH + BD-1063; bottom left:
METH + PRE; bottom right: PRE
For analysis of sigma-1 receptor puncta, first all DAPI and GFAP+ cells were
counted in each slice using Fiji ImageJ. Analysis was conducted on slices such that the
sample size was at least 15 astrocytes per group. The number of sigma-1 receptor puncta
within each cell was counted. Any puncta on or adjacent to the DAPI-stained nucleus was
categorized perinuclear while puncta in the processes were categorized as peripheral. An
example of the puncta counting Only puncta within the DAPI+ or GFAP+ area were
counted. For reconstruction of astrocytes, Bitplane Imaris 9.6 was used to generate a
surface for 5 cells per slice. For all cells, only the largest continuous surface encircling the
nucleus was considered to limit inclusion of processes from other astrocytes. Processes
were counted using the 3D reconstruction of each cell and only processes extending from
the cell body of an astrocyte were counted.
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The (+)-methamphetamine hydrochloride was purchased from Cayman Chemical
(#13997), PRE-084 from Sigma-Aldrich (P2607), and BD-1063 from Tocris (#0883). The
composition of the cutting solution was, in mM: 2 CaCl2, 3 KCl, 1 MgCl2, NaH2PO4 1.25,
NaHCO3 26, d-glucose 10, sucrose 219. All reagents were used without further
purification.

All statistics were calculated in GraphPad Prism 8.4.3. To assess homogeneity of
variance, Bartlett’s test and the Brown-Forsythe test were used. Based on the results from
the tests for differences in variance, homogeneity of variance could be assumed for all
analyses. Normal one-way ANOVA for the stellation count and the surface area to volume
ratio where therefore used and normal two-way ANOVA was used for the puncta
localization count. The method of Tukey was used to calculate adjusted p-values for
multiple comparisons for all data. Error bars in all the graphs show SEM.

3.3 Results
The volume and cell surface area data were imported from Imaris. The ratio of
surface area to volume has previously been used as a metric for astrocyte complexity in
astrocytes virally transfected with AAV5 GfaABC1D-Lck-GFP (Testen et al., 2018). Since
the fine astrocytic processes contribute to greater surface area than volume, increased
surface area:volume ratio indicates an increase in these fine processes which in turn
indicates astrocytic complexity. Here, the surface area:volume ratio is used similarly, but
on anti-GFAP stained brain slices. One-way ANOVA revealed no significant difference
was found between treatment groups on the surface area:volume ratio [F4, 29 = 0.9317; p >
0.05], suggesting that this metric may not be effective for analysis of GFAP-stained images
(Figure 3.3. It is also plausible that the length of time for incubation of slices with drugs
may have not been sufficient to evoke dramatic remodeling of the astrocytic cytoskeleton.
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Figure 3.3 The surface area:volume ratio. Astrocytes were reconstructed on Imaris and
the surface area and volume parameters were measured. There was no significant
difference between groups (n=14 cells for BD+METH; n=5 cells for all other groups)

Astrocyte stellation was analyzed as the number of primary processes (stellations)
were counted in Imaris by locating the nucleus and counting the number of GFAP+
processes extending radially from the nucleus (Figure 3.4) since the nucleus is contained
by the cell body of astrocytes. Note that astrocytes in vivo are typically already stellate
while astrocytes grown in culture are not usually stellate unless certain drugs are added to
the media. One-way ANOVA revealed a significant difference between groups [p < 0.05;
F(4, 29) = 3.913]. The method of Tukey revealed a significant difference between the METH
and the aCSF group (p < 0.05), with the METH astrocytes possessing a greater stellation
count. Treatment of METH slices with the S1R antagonist, BD-1063, abolished the
increase in stellation count (p < 0.05). However, treatment with the S1R agonist, PRE-084,
alone did not alter the ramification count relative to the aCSF control. The combination of
METH and PRE-084 reduced the ramification count relative to METH alone, but this result
did not reach statistical significance.
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Figure 3.4 The stellation counts on reconstructed astrocytes. In addition to the significant
difference between METH and aCSF, there was a significant difference (p < 0.05)
between METH and METH + BD-1063 as well as a significant difference between PRE
and METH (p < 0.05) revealed by multiple comparisons analysis.

Next, to assess whether the drug treatments altered the intracellular distribution of
the sigma-1 receptor, sigma-1 receptor immunostained puncta were counted (Figure 3.5).
Specifically, puncta within the nucleus or adjacent to the nucleus were counted as
perinuclear while puncta in GFAP+ territory were counted as peripheral. Note that this type
of analysis is not quantitative and that very bright clusters of puncta were counted as a
single punctum. In all treatment groups, most astrocytes possessed both peripheral and
perinuclear puncta, suggesting that in astrocytes, the sigma-1 receptor may be more widely
distributed throughout the cell in basal state compared to neurons. A two-way ANOVA
revealed significant main effects of treatment and localization [Treatment: F(4, 214) =
7.008, p < 0.0001; Localization: F(1, 214) = 59.70, p < 0.0001] as well as a significant
interaction effect [F(4, 214) = 6.148, p < 0.005]. Using the method of Tukey for multiple
comparisons revealed no significant difference between groups for perinuclear puncta.
However, there was a statistically significant (p < 0.05) increase in peripheral puncta for
METH-treated slices versus aCSF-treated slices. This increase was abolished by addition
of BD-1063 (p < 0.0001) and PRE-084 (p < 0.001). Contrary to observations in striatal
neurons (Francardo et al., 2014), PRE-084 did not induce redistribution of the sigma-1
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receptor relative to aCSF. In fact, in all samples, there were several puncta located in the
processes of astrocytes, far from the nucleus. Curiously, when compared to the slice
incubated with METH and PRE-084, the slice incubated in PRE-084 alone demonstrated
markedly increased peripheral puncta (p < 0.005). Thus, both BD-1063 and PRE-084
abolished the effect of METH on intracellular distribution of the sigma-1 receptor.
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Figure 3.5 The puncta count data. No significant difference was found among treatment
groups for perinuclear localization of the sigma-1 receptor.

3.4 Discussion
Methamphetamine administration has been shown to increase GFAP and sigma-1
receptor immunoreactivity (Zhang et al., 2015) in a manner that can be blocked by
treatment with the sigma-1 receptor antagonist BD-1047. Here, we provide preliminary
evidence that blockade of the sigma-1 receptor can also attenuate methamphetamineinduced increase in the stellation of astrocytes as well as the redistribution of sigma-1
receptors to the processes. Given that treatment of slices with PRE-084 alone did not induce
an increase in stellation, it is likely that sigma-1 receptor activation is not sufficient to
induce stellation. It is plausible that dopamine at dopamine receptors rather than
methamphetamine at sigma-1 receptors initiates the morphological alterations. A study in
astrocyte cell culture found that dopamine can induce rapid morphological and
transcriptomic alterations via PARP1 activation of CTCF in a manner that can be blocked
by D1 and D2 receptor antagonists (Galloway et al., 2018). However, in the case of
methamphetamine, the present data suggests that the sigma-1 receptor is involved
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somewhere in the pathway from dopamine receptor activation to morphological changes.
The sigma-1 receptor may modulate signaling via dopamine receptors at several points
along the signal transduction cascade. Since activation of the sigma-1 receptor can increase
the affinity of IP3 for IP3R3, it is possible that binding of methamphetamine to the sigma1 receptor and increased binding of dopamine to the phospholipase C-stimulating D1x
receptor can potentiate calcium release from the ER and sigma-1 receptor activation can
induce dissociation of IP3R3 from ankyrin and the sigma-1 receptor which could alter the
cellular cytoskeleton (Su and Hayashi, 2001). These experiments do not allow for the
preclusion of direct sigma-1 receptor interaction with the D1x receptor. It has been
demonstrated that the sigma-1 receptor can potentiate cAMP accumulation mediated by
the canonical Gs-coupled D1 receptor (Navarro et al., 2010). Thus, since the sigma-1
receptor forms oligomeric complexes with D1 receptors and also potentiates Gs-mediated
signaling at the D1 receptor (Fu et al., 2010), it is also plausible that the sigma-1 receptor
may act similarly with phospholipase C-stimulating dopamine receptors (D1x). See Figure
3.6 for a summary of hypothesized mechanisms by which methamphetamine can induce
alterations in astrocytic physiology.
The surprising observation that PRE-084 attenuated redistribution of the sigma-1
receptor in slices also treated with METH may be a product of two phenomena: that PRE084 attenuates METH-mediated dopamine release from neurons (Sambo et al., 2017) and
that dopamine mediates increased stellation and therefore increased cross-sectional area.
Since the technique employed in the present experiment utilized a manual count of the
individual puncta regardless of intensity or size, it is plausible that an increased density of
puncta in the METH+PRE condition made it difficult to discretize individual puncta.
Instead of forming discrete puncta, a “lawn” of sigma-1 receptor immunoreactivity was
observed. A simpler explanation is that PRE-084 is more potent at promoting the lowerorder oligomeric states of the S1R, resulting in finer, more distributed puncta. This
speculation is corroborated by findings suggesting that PRE-084 alone induces the
formation of lower-order oligomers (Schmidt et al., 2018); This would mean, presumably,
that finer puncta would be detected more easily than dense, bright puncta that may overlap
and form intense clusters rather than discrete puncta. The converse may be true of the
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M+BD condition; if BD-1063 induces the formation of higher order oligomers, clusters of
sigma-1 receptor would appear to form fewer but brighter puncta.
There were several limitations to the present work. First, utilizing the same dilution
of anti-GFAP antibody as was used in the previous experiment was not suitable for this
experiment, in which excessive GFAP-positive staining impaired identification of
individual astrocytes for 3D reconstruction. The small sample size limits the statistical
power of the stellation count, since only five astrocytes per slice could be identified for
morphological analysis in Imaris due to time limitations; future experiments should employ
either thicker striatal slices for IHC or a larger cohort of animals. Moreover, it is unclear
why the METH + PRE slice exhibited the marked decrease in peripheral sigma-1 receptor
puncta. Lastly, in order to maximize the use of the slices, the entire striatum, the dorsal
striatum was selected for analysis. It is possible that there may be regional differences in
sigma-1

receptor

expression.

Indeed,

differences

have

been

observed

in

immunocytochemical studies assessing regional expression of the sigma-1 receptor. For
example, Alonso and coworkers reported mild sigma-1 receptor immunoreactivity in the
caudate/putamen but moderate sigma-1 receptor immunoreactivity in the nucleus
accumbens (Alonso et al., 2000). Here, the striatum was treated as a whole and locations
throughout the striatum were selected.
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Figure 3.6 In the absence of sigma-1 receptor ligand, the sigma-1 receptor forms a
complex between ankyrin, IP3R3, and the spectrin/actin cytoskeleton. In the presence of
METH (black circles), the IP3R3 dissociates from ankyrin-spectrin which in turn
potentiates IP3 (green circles) binding to IP3R3. This would shift the dose-response curve
between calcium efflux and [IP3] to the left, resulting in enhanced calcium efflux from
the ER, particularly in the presence of phospholipase C signaling mediated by the D1x
receptor. Binding of agonists to the sigma-1 receptor promotes lower order oligomeric
states and dissociation from BiP. These lower order oligomeric states can translocate to
the plasma membrane and interact with D1. Whether the resulting complexes exhibit
enhanced coupling between receptor and G-proteins remains an open question
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3.5 Future Directions
While these data provide preliminary evidence for the role of the sigma-1 receptor
in methamphetamine-mediated alterations to astrocyte physiology in the dorsal striatum, it
is unclear whether these alterations also occur in the ventral striatum. One report suggests
that there is no change to the GFAP-positive processes immediately following selfadministration of methamphetamine in the nucleus accumbens (Siemsen et al., 2019),
however there are noted differences in astrocyte morphology after self-administered and
experimenter administered methamphetamine (Narita et al., 2005). Thus, in order to clarify
whether the changes to astrocyte morphology and sigma-1 receptor distribution occur in
the ventral striatum, these experiments should be repeated in slices containing the nucleus
accumbens. Moreover, given the morphological differences in astrocytes noted between
methamphetamine self-administration and experimenter-administered methamphetamine,
both methods of methamphetamine administration should be compared for effects on
redistribution of the sigma-1 receptor.
Given that GFAP is not expressed in the fine astrocytic processes that constitute
the majority of the surface area of astrocytes, utilization of both GFAP
immunohistochemistry and virally-transfected astrocyte-specific fluorescent proteins may
reveal details that could not be uncovered using the present method. For example, it is
unknown whether the sigma-1 receptor can be found in the fine, GFAP-negative processes
of astrocytes. If they can, then the puncta count data may represent an underestimate. Given
that a manual count of sigma-1 receptor puncta in anti-Sigma1 immunostained tissue is not
representative of the total expression of the sigma-1 receptor or the oligomeric status of the
sigma-1 receptor (due to the nature of antibody binding to proteins and the diffraction limit
of light microscopy), molecular approaches such as BRET would be more suited to
investigate the precise oligomeric status of sigma-1 receptors and more quantitative
approaches such as RT-qPCR could be used in future work to address the limitations of
optical methods such as immunohistochemistry in the context of determining total sigma1 receptor expression.
It is also noted that the present experiments cannot distinguish efficiently between
dopamine-mediated changes to astrocytic morphology and sigma-1 receptor-mediated
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changes to astrocytic morphology. Although PRE blocked METH-induced increases in
stellation, it is not clear whether this decreased stellation occurs due to decreased dopamine
release from neurons (Sambo et al., 2017) or direct action on sigma-1 receptors within
astrocytes. A potential future experiment could entail incubating striatal slices from three
different types of animals (wild-type, complete sigma-1 receptor knockout, and only
expressing sigma-1 receptor in GFAP-positive astrocytes) and assessing the changes in
morphology. A perhaps even simpler means of assessing the contribution of dopamine
versus the sigma-1 receptor would be to conduct the present experiments in primary
astrocyte culture. Since cultured astrocytes lack dopamine, it would be relatively
straightforward to dissociate the effects of dopamine on astrocytic morphology and the
effects of sigma-1 receptor activation on astrocytic morphology. From work in our lab, it
has been observed that addition of cocaine alone to the culture medium can induce rapid
stellation of astrocytes (Ortinski, unpublished observations), thus it is plausible that factors
other than dopamine, particularly the sigma-1 receptor, can contribute to alterations in
astrocytic morphology.
The sigma-1 receptor is a regulator of intracellular calcium dynamics (Hayashi et
al., 2000; Sambo et al., 2017). Many of the initial experiments (Hayashi et al., 2000;
Hayashi and Su, 2001; Hayashi and Su, 2007) exploring the molecular mechanisms of
sigma-1 receptor-mediated alterations in intracellular calcium utilized the NG108 cell line,
a hybrid between glioma cells (cancerous astrocytes) and neuroblastoma cells (cancerous
neuronal progenitor cells), or Chinese hamster ovarian cells. While monocultures of cells
are a valuable tool to study events on the molecular level, results obtained from
experiments using monocultures must be considered with a grain of salt, as it is not always
possible to extrapolate events that occur in culture to the situation in a living organism. For
example, it is difficult to determine whether increased dopamine or sigma-1 receptor
binding due to methamphetamine treatment are responsible for the alterations to astrocytic
physiology. Viral transfection of astrocytes in vivo with Lck-GCaMP expressed under the
GFAP promoter is a sensitive means of detecting intracellular calcium oscillations
throughout the entire astrocyte (Shigetomi et al., 2013). A potential future experiment
could involve incubating striatal brain slices in baths containing the treatment drugs in the
present experiment and observing the effects on intracellular calcium dynamics. Addition
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of selective D1 receptor antagonists to the bath could be a means of observing the
contribution of signaling via the phospholipase C-stimulating D1x receptor.
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